CN109734674B - 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途 - Google Patents

苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途 Download PDF

Info

Publication number
CN109734674B
CN109734674B CN201910139980.6A CN201910139980A CN109734674B CN 109734674 B CN109734674 B CN 109734674B CN 201910139980 A CN201910139980 A CN 201910139980A CN 109734674 B CN109734674 B CN 109734674B
Authority
CN
China
Prior art keywords
amino
methylpiperazin
preparation
biphenyl
300mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910139980.6A
Other languages
English (en)
Other versions
CN109734674A (zh
Inventor
尤启冬
郭小可
陈维琳
李冬冬
顾婧
徐俊
陈鑫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CN201910139980.6A priority Critical patent/CN109734674B/zh
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to PCT/CN2019/079160 priority patent/WO2020172932A1/zh
Priority to BR112021016861A priority patent/BR112021016861A2/pt
Priority to CA3131285A priority patent/CA3131285A1/en
Priority to US17/434,353 priority patent/US20220152027A1/en
Priority to AU2019431157A priority patent/AU2019431157A1/en
Priority to EP19917469.9A priority patent/EP3932910A4/en
Priority to JP2021549174A priority patent/JP2022526219A/ja
Priority to KR1020217030807A priority patent/KR20210137064A/ko
Priority to SG11202109305XA priority patent/SG11202109305XA/en
Priority to MX2021010218A priority patent/MX2021010218A/es
Publication of CN109734674A publication Critical patent/CN109734674A/zh
Priority to CL2021002234A priority patent/CL2021002234A1/es
Priority to IL285852A priority patent/IL285852A/en
Priority to CONC2021/0012375A priority patent/CO2021012375A2/es
Application granted granted Critical
Publication of CN109734674B publication Critical patent/CN109734674B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

本发明公开了一种WDR5蛋白‑蛋白相互作用抑制剂，包含结构如通式(I)所示的化合物。实验表明该抑制剂作用于WDR5蛋白与其相互作用蛋白包括但不局限于MLL，选择性抑制白血病细胞的增殖，在细胞水平上抑制H3K4的甲基化和下游Hox/Meis‑1基因的表达。本发明还公开了该抑制剂的制备方法以及在制备治疗急性白血病等相关疾病药物中的应用。
Figure DDA0001978201040000011

Description

苯胺类WDR5蛋白-蛋白相互作用抑制剂及其制法和用途
技术领域
本发明涉及药物化学的一种苯胺类化合物及其制法和用途，该化合物作为WDR5蛋白-蛋白相互作用抑制剂，在细胞水平抑制组蛋白的甲基转移酶的水平和下游造血基因的表达，在动物水平上抑制裸鼠移植瘤的生长，可应用于治疗急性白血病等疾病。
背景技术
WDR5蛋白由334个氨基酸组成，包含7个WD40重复的结构域。结构学研究表明WD40重复结构形成7叶螺旋桨结构，每一叶桨又含有4个反向平行的链，这样的结构特征使WDR5与许多其他蛋白相互作用WDR5-MLL1，WDR5-MYC，WDR5-MOF/HAT。WDR5还可以与H3K4me2相结合。研究表明WDR5可以稳定或组装病毒诱导的信号调节(VISA)相关复合物，在I型干扰素和抗病毒先天免疫应答中起着重要作用。WDR5蛋白在膀胱癌中也高表达，通过激活H3K4me3的表达，促进膀胱癌细胞的增殖，自我更新和化疗。WDR5作为重要的辅因子参与N-Myc-调节的转录激活和肿瘤生成。抑制WDR5蛋白作为治疗MYCN-放大的神经母细胞瘤的新型靶点。
组蛋白甲基化修饰在许多生物学过程中起到了关键作用，是表观遗传调控领域的重要研究内容。MLL1是一种组蛋白H3的4位赖氨酸(H3K4)甲基转移酶。MLL1基因易位重排形成融合基因进而表达具有致癌作用的MLL融合蛋白，从而诱发混合系白血病(mixedlineage leukemia，MLL1，急性骨髓性白血病和急性淋巴性白血病)。MLL异常引起的白血病的治疗常规化疗不理想，预后不良，目前尚无靶向药物，所以迫切需要针对该疾病的生物学性质开发新的治疗药物。
MLL1的染色体易位只发生在单等位基因上，还存在着一个野生型的MLL1。野生型的MLL1和其融合蛋白共同参与混合系白血病的发生与发展，其中野生型MLL1的酶催化活性对MLL1融合蛋白诱发白血病生成是至关重要的。因此特异性地抑制野生型MLL1的酶催化活性能达到治疗白血病的作用。
单独存在的MLL1的催化活性很差，并且仅能催化H3K4单甲基化；当MLL1与形成WDR5、RbBP5、Ash2L和DPY30，形成核心复合物后酶催化活性大大提升，尤其是对H3K4me2的催化活性。其中WDR5作为连接MLL1C-端WIN motif部分与其他蛋白的连接桥梁，对复合物的形成起着至关重要的作用。因此，利用小分子抑制剂干扰WDR5的蛋白-蛋白相互作用是抑制MLL1的酶催化活性、从而抑制下游Hox和Meis-1基因表达、进而阻断白血病进展的一种有效手段。
发明内容
发明目的：本发明的目的在于提供一种WDR5蛋白-蛋白相互作用抑制剂，在细胞水平抑制组蛋白的甲基转移酶的水平和下游造血基因的表达，在动物水平上抑制裸鼠移植瘤的生长，在治疗与MLL酶功能有关适应症药物中的应用，可应用于治疗急性白血病等疾病。
技术方案：本发明公开了一种可以干扰WDR5蛋白-蛋白相互作用的小分子化合物，其通过干扰WDR5蛋白-蛋白相互作用，抑制MLL1的甲基转移催化活性，下调Hox和Meis-1基因表达水平，从而诱导白血病细胞的凋亡，用于治疗急性白血病。本发明化合物结构如下：
Figure BDA0001978201020000021
其中X代表CH或N；
Y代表C或N；
R1、R2和R3选自氢、C1-C6烷基、C3-C6环烷基、C1-C6烷氧基取代的C1-C6烷基、硝基、卤素、氰基、醛基、羟基、-NR7R8，或者R2、R3连接形成的
Figure BDA0001978201020000022
其中R7、R8代表氢或C1-C4烷基或者R7、R8连接形成的3-7元含氮杂环；
R4代表吗啉基、哌嗪基、4-取代哌嗪基，4-取代高哌嗪基，3-取代哌嗪基或2-取代哌嗪基，取代基为C1-C4烷基，3-7元环烷基，羟烷基，苯基；
R5代表硝基、氨基、苯基、取代苯基、含氧或氮的5-6元芳杂环、取代的含氧或氮的5-6元芳杂环、-NHCOR9；其中R9代表羟基、C1～C6烷氧基、苯基、取代苯基、含氧或氮的5-6元芳杂环、取代的含氧或氮的5-6元芳杂环，取代基是C1-C4烷基、C1-C4烷氧基、卤素、氰基、-NHCOR10、-CONR11R12或-COOR10，其中R10代表氢、C1-C6烷基、C1-C6氨基取代烷基、3～7元环烷基、含氮或含氧的3～7元杂环、苯基；R11、R12代表氢、C1-C6烷基、苯基或取代苯基、取代的或未取代的含氮或含氧3～7元杂环或R11、R12连接形成含氮或含氧的3～7元杂环；
R6代表氢、卤素、甲基、三氟甲基、氨基、取代氨基，取代基是C1-C4烷基、烯丙基；
R1、R2和R3选自氢、甲基、甲氧基、硝基、卤素、氰基、醛基、-NR7R8，或者R2、R3连接形成的
Figure BDA0001978201020000023
其中R7、R8代表氢或C1-C4烷基或者R7、R8连接形成的3-5元含氮杂环；
R4优选吗啉基、哌嗪基、4-取代哌嗪基、取代基是甲基、乙基、环丙基、羟乙基、苯基；
R5优选硝基、氨基、-NHCOR9、呋喃基、嘧啶基、吡啶基、取代三氮唑、取代苯基，取代基为单或双取代的卤素、-NHCOR10、-CONR11R12或-COOR10；R9代表苯基；R10代表氢、C1-C6烷基、C1-C6氨基取代烷基、3～7元环烷基、含氮或含氧的3～7元杂环、苯基；R11、R12代表氢、C1-C6烷基、苯基或取代苯基、取代的或未取代的含氮或含氧3～7元杂环或R11、R12连接形成含氮或含氧的3～7元杂环。
本发明同时包括化合物(I)的药学上可接受的盐，及其溶剂化物，都与化合物(I)有同样的药理功效。
本发明公开了一种药物组合物，其包含化合物(I)或其可药用盐，或溶剂合物，以及一种或多种可药用载体、稀释剂和赋形剂。
本发明还提供式(I)化合物或其可药用盐或溶剂合物在制备用于通过抑制WDR5蛋白-蛋白相互作用来治疗该酶介导的疾病的药物中的用途，所述疾病如MLL基因融合型白血病，其可通过抑制MLL1的酶活性来治疗。
本发明的化合物临床所用剂量为0.01mg～1000mg/天，也可以根据病情的轻重或剂型的不同偏离此范围。
在某些实施方案中，根据式(I)的化合物可含有足以形成盐的碱性官能团。代表性的盐包括药用无机酸盐，有盐酸盐、氢溴酸盐和硫酸盐；药用有机酸盐，优选乙酸盐、三氟乙酸盐、乳酸盐、琥珀酸盐、富马酸盐、马来酸盐、柠檬酸盐、苯甲酸盐、甲磺酸盐、对苯甲酸盐和对苯甲磺酸盐。
同时本发明还公开了式(I)相关化合物的制备方法，所述制备方法包括如下方法：
Figure BDA0001978201020000031
或：
Figure BDA0001978201020000032
或：
Figure BDA0001978201020000041
有益效果：本发明的苯胺类化合物具有较强的WDR5蛋白-蛋白相互作用抑制活性，可以在细胞水平降低MLL1酶催化活性、下调Hox和Meis-1基因表达，治疗与WDR5酶功能有关适应症，有关适应症指血液性肿瘤，包括急性白血病等疾病。
附图说明
图1是Western-blot实验检测实施例72在细胞内对MLL1酶催化活性的影响；
图2是RT-PCR实验检测实施例72在细胞内对下调Hoxa9和Meis-1基因表达；
图3是MV4-11裸鼠移植瘤模型检测实施例72在动物水平对肿瘤的抑制水平。
具体实施方式
实施例1
Figure BDA0001978201020000042
N-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)喹唑啉-4-胺
步骤1：2-(4-甲基哌嗪-1-基)-5-硝基苯胺的制备
将2-氟-5-硝基苯胺(2g,12.8mmol)溶于DMF(20mL)中，加入DIPEA(3.3g,25.6mmol)和1-甲基哌嗪(25.6mmol)，100℃下搅拌反应8h。在反应液中加入100mL水，乙酸乙酯萃取(3×50mL)，合并有机层，并用无水Na2SO4干燥，减压蒸馏后得到粗品，用CH3CN洗涤得到黄色固体，收率53.0％；m.p.200℃-202℃；1H NMR(300MHz,DMSO-d6)δ7.53(d,J＝2.4Hz,1H),7.42(dd,J＝8.8,2.4Hz,1H),7.04(d,J＝8.7Hz,1H),5.26(s,2H),3.11(s,4H),2.58(s,4H),2.24(s,3H).HRMS(ESI):calcd.form/z C11H17N4O2,[M+H]+237.1316,found237.1342.
步骤2：标题化合物N-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)喹唑啉-4-胺的制备
将2-(4-甲基哌嗪-1-基)-5-硝基苯胺(0.2g,0.846mmol)溶于异丙醇(10mL)中，加入1mL浓HCl和4-氯喹唑啉(0.27g,1.69mmol)回流18h，减压蒸馏至有固体析出，冷却，抽滤，滤饼用异丙醇(5mL×3)洗涤，干燥得到黄色固体，收率63.5％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ9.57(s,1H),8.61(s,2H),8.43(s,1H),8.07(s,1H),7.86(d,J＝10.0Hz,2H),7.69(s,1H),7.30(s,J＝8.8Hz,1H),3.09(s,4H),2.32(s,4H),2.13(s,3H).HRMS(ESI):calcd.form/z C19H20N6O2,[M+H]+365.1720,found 365.1722.HPLC(100％MeOH):tR＝7.772min,99.16％.
实施例2
Figure BDA0001978201020000051
6-氯-N-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)嘧啶-4-胺
按实施例1步骤2的方法，用4，6-二氯嘧啶(1.69mmol)替换4-氯喹唑啉得黄色固体，收率65.8％；m.p.169℃-171℃；1H NMR(300MHz,DMSO-d6)δ9.36(s,1H),8.48(s,1H),8.42(d,J＝2.7Hz,1H),8.02(dd,J＝8.9,2.8Hz,1H),7.23(d,J＝9.0Hz,1H),6.81(s,1H),3.04(t,J＝4.6Hz,4H),2.35(t,J＝4.7Hz,4H),2.16(s,3H).HRMS(ESI):calcd.form/zC15H17ClN6O2,[M+H]+349.1174,found 349.1177.HPLC(100％MeOH):tR＝6.097min,96.84％.
实施例3
Figure BDA0001978201020000052
N4，N4-二甲基-N6-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)嘧啶-4,6-二胺
将实施例2(0.35mmol)溶解在DMF(5mL)中，加入DIPEA(1.5mmol)和二甲基胺(1mmol),在120℃条件下反应4h,反应液用乙酸乙酯(20mL)稀释，水洗(10mL×3)，饱和氯化钠洗涤，有机层用无水硫酸钠干燥，抽滤，旋干，粗品用硅胶柱层析(二氯甲烷:甲醇＝50:1)得到黄色固体。收率49.5％；m.p.152℃-154℃；1H NMR(300MHz,CDCl3)δ8.69(d,J＝2.7Hz,1H),8.28(s,1H),7.80(dd,J＝8.7,2.7Hz,1H),7.06(d,J＝8.8Hz,1H),6.94(s,1H),5.82(s,1H),3.03(s,6H),2.94(t,J＝4.8Hz,4H),2.65-2.48(m,4H),2.30(s,3H).HRMS(ESI):calcd.form/z C17H23N7O2,[M+H]+358.1986,found 358.1992.HPLC(100％MeOH):tR＝4.709min,99.20％.
实施例4
Figure BDA0001978201020000053
6-氯-2-甲基-N-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)嘧啶-4-胺
按照实施例1步骤2的方法，用4,6-二氯-2-甲基嘧啶替换4-氯喹唑啉得黄色固体，收率44.8％；m.p.196℃-198℃；1H NMR(300MHz,CDCl3)δ9.09(d,J＝2.6Hz,1H),7.97(dd,J＝8.8,2.7Hz,1H),7.55(s,1H),7.23(s,1H),6.59(s,1H),3.02(t,J＝4.8Hz,4H),2.65-2.61(m,7H),2.40(s,3H).HRMS(ESI):calcd.form/z C16H19ClN6O2,[M+H]+363.1331,found363.1335.HPLC(100％MeOH):tR＝8.574min,97.99％.
实施例5
Figure BDA0001978201020000061
6-氯-N4-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)嘧啶-2,4-二胺
按照实施例1步骤2的制备方法，用4,6-二氯-2-氨基嘧啶替换4-氯喹唑啉得黄色固体，收率77.6％；m.p.248℃-251℃；1H NMR(300MHz,CDCl3)δ9.13(s,1H),7.94(dd,J＝8.7,2.6Hz,1H),7.41(s,1H),7.20(d,J＝2.6Hz,1H),5.16(s,2H),3.00(t,J＝4.8Hz,4H),2.64(s,4H),2.41(s,3H).HRMS(ESI):calcd.form/z C15H18ClN7O2,[M+H]+364.1283,found364.1289.HPLC(100％MeOH):tR＝5.850min,97.14％.
实施例6
Figure BDA0001978201020000062
6-氯-5-甲基-N-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)嘧啶-4-胺
按照实施例1步骤2的制备方法，用4,6-二氯-5-甲基嘧啶替换4-氯喹唑啉得黄色固体,收率60.5％；m.p.259℃-261℃；1H NMR(300MHz,CDCl3)δ9.55(s,1H),8.57(s,1H),8.18(s,1H),7.95(dd,J＝8.7,2.7Hz,1H),7.27(s,1H),3.02(t,J＝4.8Hz,4H),2.66(s,4H),2.42(s,6H).HRMS(ESI):calcd.form/z C16H19ClN6O2,[M+H]+363.1331,found363.1349.HPLC(100％MeOH):tR＝7.673min,97.05％.
实施例7
Figure BDA0001978201020000063
6-氯-N4-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)嘧啶-4,5-二胺
按照实施例1步骤2的制备方法，用4,6-二氯-5-氨基嘧啶替换4-氯喹唑啉得黄色固体，收率84.7％；m.p.185℃-187℃；1H NMR(300MHz,DMSO-d6)δ8.65(d,J＝2.6Hz,1H),8.22(s,1H),7.98-7.91(m,2H),7.27(d,J＝8.9Hz,1H),5.41(s,2H),2.91(br s,4H),2.47(br s,4H),2.20(s,3H).HRMS(ESI):calcd.form/z C15H18ClN7O2,[M+H]+364.1283,found364.1286.HPLC(100％MeOH):tR＝6.581min,98.22％.
实施例8
Figure BDA0001978201020000064
6-氯-2-甲基-N4-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)嘧啶-4,5-二胺
按照实施例1步骤2的制备方法，用4,6-二氯2-甲基-5-氨基嘧啶替换4-氯喹唑啉得黄色固体，收率67.8％；m.p.248℃-250℃；1H NMR(300MHz,DMSO-d6)δ8.87(d,J＝2.8Hz,1H),8.22(s,1H),7.94(dd,J＝8.8,2.8Hz,1H),5.12(s,2H),2.98(t,J＝4.8Hz,4H),2.46(s,4H),2.32(s,3H),2.21(s,3H).HRMS(ESI):calcd.form/z C16H20ClN7O2,[M+H]+378.1440,found 378.1440.HPLC(100％MeOH):tR＝6.251min,97.99％.
实施例9
Figure BDA0001978201020000071
N4-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)嘧啶-4,5-二胺
按照实施例1步骤2的制备方法，用4-氯-5-氨基嘧啶替换4-氯喹唑啉得黄色固体，收率43.7％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ8.25(s,1H),7.82(dd,J＝7.4,1.9Hz,1H),7.81-7.77(m,2H),7.67(s,1H),7.04(d,J＝7.5Hz,1H),5.82(s,2H),3.20(t,J＝5.3Hz,4H),2.98(t,J＝5.3Hz,4H),2.60(s,3H).HRMS(ESI):calcd.form/z C15H19N7O2,[M+H]+330.1673,found 330.1675.HPLC(100％MeOH):tR＝7.673min,97.05％
实施例10
Figure BDA0001978201020000072
N-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)嘧啶-2-胺
按照实施例1步骤2的制备方法，用2-溴嘧啶替换4-氯喹唑啉得黄色固体，收率57.5％；m.p.195℃-197℃；1H NMR(300MHz,CDCl3)δ9.47(s,1H),8.54(d,J＝3.0Hz,2H),8.03(s,1H),7.88(d,J＝3.0Hz,1H),7.22(d,J＝9.0Hz,1H),6.85(t,J＝9.0Hz,1H),3.04(t,J＝5.6Hz,4H),2.70(br s,4H),2.42(s,3H).HRMS(ESI):calcd.form/z C15H18ClN7O2,[M+H]+315.1564,found 315.1566.HPLC(100％MeOH):tR＝16.340min,96.09％.
实施例11
Figure BDA0001978201020000073
N2-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)嘧啶-2,4-二胺
按照实施例1步骤2的制备方法，用2-氯嘧啶-4-胺替换4-氯喹唑啉得黄色固体，收率45.7％；m.p.210℃-212℃；1H NMR(300MHz,DMSO-d6)δ9.30(s,1H),7.94(d,J＝6.0Hz,1H),7.80(dd,J＝8.7Hz,1H),7.63(s,1H),7.32(d,J＝8.8Hz,1H),6.81(br s,2H),6.03(d,J＝5.8Hz,1H),2.93(t,J＝4.7Hz,4H),2.54(br s,4H),2.26(s,3H).HRMS(ESI):calcd.form/z C15H19N7O2,[M+H]+330.1673,found 330.1679.HPLC(100％MeOH):tR＝6.354min,96.85％.
实施例12
Figure BDA0001978201020000081
N2-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)吡啶-2,3-二胺
按照实施例1步骤2，用2-氯吡啶-3-胺替换4-氯喹唑啉得黄色固体，收率36.6％；m.p.210℃-212℃；1H NMR(300MHz,DMSO-d6)δ9.06(d,J＝2.8Hz,1H),7.77(dd,J＝8.8,2.8Hz,1H),7.68-7.59(m,2H),7.28(d,J＝8.8Hz,1H),7.77(dd,J＝7.6,1.7Hz,1H),6.75(dd,J＝7.6,1.7Hz,1H),4.94(s,2H),2.90(t,J＝4.8Hz,4H),2.54(s,4H),2.25(s,3H).HRMS(ESI):calcd.form/z C15H20N6O2,[M+H]+329.1720,found 329.1722.HPLC(100％MeOH):tR＝4.151min,95.29％.
实施例13
Figure BDA0001978201020000082
6-氯-N-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)-5-硝基嘧啶-4-胺
按照实施例1步骤2的制备方法，用4,6-二氯-5-硝基嘧啶替换4-氯喹唑啉得黄色固体，收率53.2％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ10.20(s,1H),8.85(d,J＝6.5Hz,1H),8.16(d,J＝6.0Hz,2H),7.62(t,J＝9.5Hz,1H),3.52(br s,4H),2.42(br s,4H),2.22(s,3H).HRMS(ESI):calcd.form/z C15H16ClN7O4,[M+H]+394.0671,found 394.0674.HPLC(100％MeOH):tR＝6.083min,97.01％.
实施例14
Figure BDA0001978201020000083
4-氯-6-((2-(4-甲基哌嗪-1-基)-5-硝基苯基)氨基)嘧啶-5-甲腈
按照实施例1步骤2的制备方法，用4,6-二氯嘧啶-5-甲腈替换4-氯喹唑啉得黄色固体，收率82.7％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ8.39(d,J＝2.8Hz,1H),8.22(s,1H),8.06(dt,J＝9.0,3.1Hz,1H),7.32(d,J＝8.9Hz,1H),3.21(br s,4H),2.84(br s,4H),2.47(s,3H).HRMS(ESI):calcd.form/z C16H16ClN7O2,[M+H]+374.1133,found374.1135.HPLC(100％MeOH):tR＝5.679min,98.83％.
实施例15
Figure BDA0001978201020000091
4-氯-6-((2-(4-甲基哌嗪-1-基)-5-硝基苯基)氨基)嘧啶-5-甲醛
按照实施例1步骤2的制备方法，用4,6-二氯嘧啶-5-甲醛替换4-氯喹唑啉得黄色固体，收率：75.9％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ11.93(s,1H),10.05(s,1H),9.05(d,J＝2.6Hz,1H),8.36(d,J＝1.6Hz,1H),8.01(dt,J＝8.9,2.3Hz,1H),7.36(dd,J＝8.9,1.8Hz,1H),3.04-2.87(m,4H),2.56(t,J＝4.6Hz,4H),2.26(s,3H).HRMS(ESI):calcd.form/z C16H17ClN6O3,[M+H]+377.1130,found 377.1132.HPLC(100％MeOH):tR＝6.472min,98.17％.
实施例16
Figure BDA0001978201020000092
6-氯-5-甲氧基-N-(2-(4-甲基哌嗪-1-基)-5-硝基苯基)嘧啶-4-胺
按照实施例1步骤2的制备方法，用4,6-二氯嘧啶-5-甲醛替换4-氯喹唑啉得黄色固体，收率88.9％；m.p.>250℃；1H NMR(300MHz,CDCl3)δ9.59(d,J＝2.7Hz,1H),8.68(s,1H),8.45(d,J＝3.5Hz,1H),7.96(dd,J＝8.8,2.7Hz,1H),7.26(d,J＝2.1Hz,1H),4.06(s,1H),3.06-2.97(m,4H),2.67(br s,4H),2.42(s,3H).HRMS(ESI):calcd.form/zC16H19ClN6O3,[M+H]+379.1280,found 379.1286.HPLC(100％MeOH):tR＝6.614min,95.68％.
实施例17
Figure BDA0001978201020000093
6-氯-N4-(5-硝基-2-(哌嗪-1-基)苯基)嘧啶-4,5-二胺
步骤1：6-氯-N4-(2-氟-5-硝基苯基)嘧啶-4,5-二胺的制备
将2-氟-5-硝基苯胺(2g,12.8mmol)溶于异丙醇(50mL)中，加入2mL的浓硫酸和4,6-二氯-5-氨基嘧啶(25.6mmol)，回流18h，将反应液旋至有固体析出，冷却析出固体，抽滤，滤饼用异丙醇(5mL×3)洗涤，干燥得黄色固体。收率59.5％；m.p.209℃-211℃；1H-NMR(300MHz,DMSO-d6)δ9.14(s,1H),8.65-8.62(m,1H),8.06-8.03(m,1H),7.86(s,1H),7.58-7.54(m,1H),5.54(s,2H).m/z(EI-MS):284.1[M]+.
步骤2：目标产物6-氯-N4-(5-硝基-2-(哌嗪-1-基)苯基)嘧啶-4,5-二胺的制备
将6-氯-N4-(2-氟-5-硝基苯基)嘧啶-4,5-二胺(0.35mmol)溶于5mL DMF中，加入DIPEA(1.5mmol)和叔丁基哌嗪-1-羧酸酯(1.0mmol)，在50℃下反应5h，反应液用乙酸乙酯(20mL)稀释,水洗(10mL×3)，饱和氯化钠洗涤，有机层用无水硫酸钠干燥，旋干，得到的粗品溶于二氯甲烷中(20mL),滴加三氟醋酸(2mL),在室温下反应2h，反应液用饱和碳酸氢钠中和至不在有气泡产生，乙酸乙酯萃取，旋干得黄色固体，用CH3CN洗涤，干燥，收率65.6％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ9.09(br s,1H),8.60(d,J＝2.7Hz,1H),8.33(s,1H),7.89(dd,J＝8.9,2.7Hz,1H),7.83(s,1H),7.23(d,J＝8.9Hz,1H),5.55(s,2H),3.21(s,4H),3.42(t,J＝6.0Hz,4H).HRMS(ESI):calcd.form/z C14H17ClN7O2,[M+H]+350.1127,found 350.1131.HPLC(100％MeOH):tR＝4.069min,96.17％.
实施例18
Figure BDA0001978201020000101
6-氯-N4-(2-吗啉代-5-硝基苯基)嘧啶-4,5-二胺
将6-氯-N4-(2-氟-5-硝基苯基)嘧啶-4,5-二胺(0.35mmol)溶于5mL DMF中，加入DIPEA(1.5mmol)和吗啉(1.0mmol)，在50℃下反应5h，反应液用乙酸乙酯(20mL)稀释,水洗(10mL×3)，饱和氯化钠洗涤，有机层用无水硫酸钠干燥，旋干，得到的粗品，用CH3CN洗涤，干燥，收率71.4％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ8.70(s,1H),8.32(s,1H),8.08-7.86(m,2H),7.29(d,J＝9.0Hz,1H),5.46(s,2H),3.73(s,4H),2.99(s,4H).HRMS(ESI):calcd.form/z C14H16ClN6O3,[M+H]+351.0967,found 351.0967.HPLC(100％MeOH):tR＝7.041min,98.84％.
实施例19
Figure BDA0001978201020000102
6-氯-N4-(2-(4-乙基哌嗪-1-基)-5-硝基苯基)嘧啶-4,5-二胺
按照实施例18步骤2的制备方法，用1-乙基哌嗪替换吗啉的黄色固体，收率46.7％；m.p.185℃-187℃；1H NMR(300MHz,CDCl3)δ9.34(s,1H),8.32(s,1H),8.18(s,1H),7.93(dt,J＝8.8,2.7Hz,1H),7.27-7.20(m,1H),3.60(s,2H),3.08-2.93(m,4H),2.70(s,4H),2.53(qd,J＝7.2,2.7Hz,2H),1.16(td,J＝7.3,2.7Hz,3H).HRMS(ESI):calcd.form/zC16H21ClN7O2,[M+H]+378.1440,found 348.1449.HPLC(100％MeOH):tR＝4.542min,97.65％.
实施例20
Figure BDA0001978201020000111
6-氯-N4-(2-(4-环丙基哌嗪-1-基)-5-硝基苯基)嘧啶-4,5-二胺
按照实施例18步骤2的制备方法，用1-环丙基哌嗪替换吗啉的黄色固体，收率58.9％；m.p.223℃-225℃；1H NMR(300MHz,CDCl3)δ9.35(d,J＝2.7Hz,1H),8.32(s,1H),8.21(s,1H),7.92(dd,J＝8.7,2.7Hz,1H),3.62(s,2H),2.96(t,J＝4.7Hz,4H),2.87(s,4H),1.78-1.71(m,1H),0.56-0.51(m,2H),0.49-0.44(m,2H).HRMS(ESI):calcd.form/zC17H21ClN7O2,[M+H]+390.1440,found 390.1446.HPLC(100％MeOH):tR＝4.811min,99.31％.
实施例21
Figure BDA0001978201020000112
2-(4-(2-((5-氨基-6-氯嘧啶-4-基)氨基)-4-硝基苯基)哌嗪-1-基)乙-1-醇
按照实施例18步骤2的制备方法，用2-(哌嗪-1-基)乙-1-醇替换吗啉的黄色固体，收率76.4％；m.p.202℃-204℃；1H NMR(300MHz,CDCl3)δ9.33(s,1H),8.32(s,1H),8.15(s,1H),7.94(d,J＝8.7Hz,1H),7.27(s,1H),3.70(s,2H),3.64-2.46(m,2H),3.02(s,4H),2.78(s,4H),2.68(s,2H),2.57(s,1H).HRMS(ESI):calcd.form/z C16H20ClN7O3,[M+H]+394.1389,found 394.1387.HPLC(100％MeOH):tR＝7.347min,96.12％.
实施例22
Figure BDA0001978201020000113
6-氯-N4-(5-硝基-2-(4-苯基哌嗪-1-基)苯基)嘧啶-4,5-二胺
按照实施例18步骤2的制备方法，用1-苯基哌嗪替换吗啉的黄色固体，收率76.4％；m.p.>250℃；1H NMR(300MHz,CDCl3)δ9.39(d,J＝2.7Hz,1H),8.35(s,1H),8.25(s,1H),7.97(dd,J＝8.9,2.6Hz,1H),7.39-7.28(m,3H),7.06-6.90(m,3H),3.54(s,2H),3.44(t,J＝4.9Hz,4H),3.16(t,J＝4.9Hz,4H).HRMS(ESI):calcd.form/z C20H20ClN7O2,[M+H]+426.1440,found 426.1449.HPLC(100％MeOH):tR＝4.905min,95.52％.
实施例23
Figure BDA0001978201020000121
(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)(吗啉代)甲酮
步骤1：4'-氟-3'-硝基-[1,1'-联苯基]-4-羧酸甲酯的制备
将4-溴-1-氟-2硝基苯(5.0g,22.8mmol)溶在1,4-二氧六环(100mL)中，加入(4-(甲氧基羰基)苯基)硼酸(27.3mmol)中，加入碳酸铯(14.8g,45.6mmol)和催化量的Pd(PPh3)2Cl2，N2保护下回流20h，过滤除掉催化剂和碳酸铯，旋干后的粗品柱层析(二氯甲烷：甲醇＝50:1)得白色固体，收率69.9％；m.p.145℃-147℃.1H NMR(300MHz,CDCl3)δ8.31-8.13(m,3H),7.88-7.59(m,1H),8.28(m,3H),7.42-7.36(m,1H),3.94(s,3H).m/z(EI-MS):276.2[M]+.
步骤2：4′-(4-甲基哌嗪-1-基)-3′-硝基-[1,1′-联苯]-4-羧酸甲酯的制备
按照实施例1步骤1的制备方法，将2-F-5-硝基苯胺替换成4′-氟-3′-硝基-[1,1′-联苯基]-4-羧酸甲酯得黄色固体，收率93.8％；m.p.130℃-132℃；1H NMR(300MHz,CDCl3)δ8.11(dd,J＝6.8,1.9Hz,2H),8.05(d,J＝2.3Hz,1H),7.44(dd,J＝8.6,2.3Hz,1H),7.68-7.61(m,2H),7.21(d,J＝8.6Hz,1H),3.95(s,3H),3.16(t,J＝4.7Hz,4H),2.61(t,J＝4.7Hz,4H),2.38(s,3H).m/z(EI-MS):356.2[M]+.
步骤3：3′-氨基-4′-(4-甲基哌嗪-1-基)-[1,1′-联苯基]-4-羧酸甲酯的制备
将4′-(4-甲基哌嗪-1-基)-3′-硝基-[1,1′-联苯]-4-羧酸甲酯(12.9mmol)溶于甲醇中，加入催化量的Pd/C,H2保护下室温搅拌2h，过滤旋干得灰白色固体。收率90.4％；m.p.229℃-231℃；1H NMR(300MHz,CDCl3)δ8.07(d,J＝8.5Hz,2H),7.61((dd,J＝6.7,1.8Hz,2H),7.09(d,J＝8.5Hz,1H),7.03(m,2H),4.06(s,2H),3.93(s,3H),3.01(t,J＝4.4Hz,4H),2.61(s,4H),2.38(s,3H).m/z(EI-MS):326.2[M]+.
步骤4：3'-((5-氨基-6-氯嘧啶-4-基)氨基)-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸甲酯的制备
将4,6-二氯-5-硝基嘧啶(7.40g,38.11mmol)溶于四氢呋喃(50mL)中，加入三乙胺(3.17mL,22.86mmol)，0℃下滴加3'-氨基-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸甲酯的四氢呋喃溶液，升至室温搅拌6h，旋干，粗品硅胶柱层析(二氯甲烷：甲醇＝100:1)分离得黄色固体，继续溶于乙酸乙酯中，加入SnCl2(3倍当量)回流4h,用饱和碳酸氢钠调节至不再有气泡产生，抽滤，滤饼用乙酸乙酯洗涤(4×20mL)，滤液用乙酸乙酯萃取(4×50mL)，合并有机层，干燥，旋干得到米白色固体，收率45.7％；m.p.209℃-210℃；1H NMR(300MHz,DMSO-d6)δ8.53-8.42(m,1H),8.23(s,1H),7.96-7.90(m,3H),7.70(d,J＝8.4Hz,2H),7.46-7.42(m,1H),7.26(d,J＝8.3Hz,1H),5.36(s,2H),3.93(s,3H),3.57(t,J＝4.6Hz,4H),2.87(t,J＝4.7Hz,4H),2.24(s,3H).m/z(EI-MS):453.2[M]+.
步骤5:3'-((5-氨基-6-氯嘧啶-4-基)氨基)-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸的制备
将3'-((5-氨基-6-氯嘧啶-4-基)氨基)-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸甲酯溶于甲醇(50mL)中，加入氢氧化锂(1M,10mL)，室温搅拌2h，用1M HCl调节至有大量固体析出，抽滤，干燥得白色固体，收率80.0％；m p.>250℃；1H NMR(300MHz,DMSO-d6)δ8.33-8.28(m,2H),8.10(s,1H),7.86-7.84(m,2H),7.80(s,1H),7.13-7.11(m,2H),6.88(d,J＝2.0Hz,1H),5.42(s,2H),3.54(t,J＝4.6Hz,4H),2.35(t,J＝4.7Hz,4H),2.24(s,3H).m/z(EI-MS):439.3[M]+
步骤6：目标产物:(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-4”-(4-甲基哌嗪-1-基)-[1,1′-联苯]-4-基)(吗啉代)甲酮的制备
将3′-((5-氨基-6-氯嘧啶-4-基)氨基)-4′-(4-甲基哌嗪-1-基)-[1,1′-联苯基]-4-羧酸甲酯(0.1g,0.26mmol)溶于DMF(10mL)中，加入缩合剂BOP(0.22g,0.49mmol)和三乙胺(0.12mL,0.88mmol)，室温搅拌30min后加入吗啉(0.39mmol)，室温搅拌12h后，将反应液倒入水中(50mL),乙酸乙酯萃取(3×50mL)，有机层用无水硫酸钠干燥，过滤，旋干，柱层析分离纯化(二氯甲烷：甲醇＝50:1)得白色固体，收率67.8％；m.p.225℃-227℃；1H NMR(300MHz,DMSO-d6)δ8.45(d,J＝13.6Hz,2H),7.90(s,1H),7.69(d,J＝7.9Hz,2H),7.49(d,J＝7.7Hz,2H),7.42(d,J＝8.4Hz,1H),7.27(d,J＝8.2Hz,1H),5.39(s,2H),3.61(s,4H),3.35(s,4H),2.98-2.90(s,4H),2.64(s,4H),2.34(s,3H).HRMS(ESI):calcd.form/zC26H30ClN7O2,[M+H]+508.2222,found 508.2223.HPLC(80％methanol in water):tR＝3.507min,98.81％.
实施例24
Figure BDA0001978201020000131
3”-((5-氨基-6-氯嘧啶-4-基)氨基)-4”-(4-甲基哌嗪-1-基)-N-(2-吗啉代乙基)-[1,1'-联苯]-唑-4-甲酰胺
按照实施例23步骤6的制备方法，用2-吗啉乙基-1-胺替换吗啉得白色固体，收率55.8％；m.p.230℃-232℃；1H NMR(300MHz,DMSO-d6)δ8.45(s,1H),8.27-8.22(m,2H),7.92-7.90(m,3H),7.71(d,J＝8.0Hz,2H),7.45(d,J＝8.2Hz,1H),7.26(d,J＝8.4Hz,1H),5.39(s,2H),3.58(s,4H),3.40-3.34(m,4H),2.90(s,4H),2.61(s,4H),2.44(s,4H),2.31(s,3H).HRMS(ESI):calcd.form/z C28H35ClN8O2,[M+H]+551.2644,found 551.2639.HPLC(80％methanol in water):tR＝3.196min,98.91％.
实施例25
Figure BDA0001978201020000141
3”-((5-氨基-6-氯嘧啶-4-基)氨基)-4”-(4-甲基哌嗪-1-基)-N-(3-吗啉代丙基)-[1,1'-联苯]-唑-4-甲酰胺
按照实施例23步骤6的制备方法，用3-吗啉丙基-1-胺替换吗啉得白色固体，收率48.9％；m.p.210℃-212℃；1H NMR(300MHz,DMSO-d6)δ8.53-8.42(m,1H),8.28(d,J＝2.8Hz,1H),8.23(s,1H),7.96-7.90(m,3H),7.70(d,J＝8.4Hz,2H),7.46-7.42(m,1H),7.26(d,J＝8.3Hz,1H),5.36(s,2H),3.57(t,J＝4.6Hz,4H),3.32-3.30(m,2H),2.87(t,J＝4.7Hz,4H),2.51-2.49(m,4H),2.37-2.32(m,6H),2.24(s,3H).HRMS(ESI):calcd.form/z C29H31ClN8O2,[M+H]+565.2801,found 565.2801.HPLC(80％methanol in water):tR＝3.974min,96.00％.
实施例26
Figure BDA0001978201020000142
3”-((5-氨基-6-氯嘧啶-4-基)氨基)-N，N-二甲基-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-甲酰胺
按照实施例23步骤6的制备方法，用二甲基胺替换吗啉得白色固体，收率78.9％；m.p.142℃-145℃；1H NMR(300MHz,DMSO-d6)δ8.24(s,1H),7.70(s,2H),7.56-7.41(m,5H),7.02(s,1H),5.57(s,2H),3.19-3.97(m,10H),2.75(s,4H),2.43(s,3H).HRMS(ESI):calcd.form/z C24H28ClN7O,[M+H]+466.2117,found 466.2121.HPLC(80％methanol inwater):tR＝2.489min,95.56％.
实施例27
Figure BDA0001978201020000143
(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-4”-(4-甲基哌嗪-1-基)-[1,1′-联苯]-4-基)(4-甲基哌嗪-1-基)甲酮
按照实施例23步骤6的制备方法，用1-甲基哌嗪替换吗啉得白色固体，收率56.9％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ8.54(d,J＝13.6Hz,2H),7.90(s,1H),7.68(d,J＝7.9Hz,2H),7.45(d,J＝7.7Hz,2H),7.39(d,J＝8.4Hz,1H),7.27(d,J＝8.1Hz,1H),5.35(s,2H),3.61(s,4H),3.35(s,4H),2.98-2.90(s,4H),2.64(s,4H),2.34(s,3H),2.30(s,3H).HRMS(ESI):calcd.form/z C27H33ClN8O,[M+H]+521.2937,found521.2937.HPLC(80％methanol in water):tR＝4.094min,98.10％.
实施例28
Figure BDA0001978201020000151
3”-((5-氨基-6-氯嘧啶-4-基)氨基)-N-(3-(二甲基氨基)丙基)-4”-(4-甲基哌嗪-1-基)-[1,1′-联苯]-4-甲酰胺
按照实施例23步骤6的制备方法，用N1，N1-二甲基-1,3-二胺替换吗啉得白色固体，收率38.9％；m.p.232℃-234℃；1H NMR(300MHz,DMSO-d6)δ8.66(s,1H),8.26-8.20(m,2H),7.93-7.88(m,3H),7.73(d,J＝9.8Hz,2H),7.47(s,1H),7.29(s,1H),5.44(s,2H),3.08-2.90(m,8H),2.77(s,6H),2.50(s,4H),1.90(s,4H),1.28-1.23(m,2H).HRMS(ESI):calcd.form/z C27H36ClN8O,[M+H]+523.2695,found 523.2695.HPLC(90％methanol inwater):tR＝3.409min,98.88％.
实施例29
Figure BDA0001978201020000152
3”-((5-氨基-6-氯嘧啶-4-基)氨基)-4”-(4-甲基哌嗪-1-基)-N-(2-(吡咯烷-1-基)乙基)-[11,1′-联苯基]-4-甲酰胺
按照实施例23步骤6的制备方法，用2-(吡咯烷-1-基)乙-1-胺替换吗啉得白色固体，收率37.8％；m.p.241℃-243℃；1H NMR(300MHz,DMSO-d6)δ8.67(s,1H),8.25-8.22(m,2H),7.93-7.88(m,3H),7.73(d,J＝9.8Hz,2H),7.47(s,1H),7.29(s,1H),5.64(s,2H),3.64-3.62(m,2H),3.38-3.34(m,6H),3.12(s,4H),2.54(s,2H),2.48(s,2H),2.36(s,3H),1.93(s,4H).HRMS(ESI):calcd.form/z C28H35ClN8O,[M+H]+535.2695,found535.2690.HPLC(100％methanol):tR＝7.516min,98.64％.
实施例30
Figure BDA0001978201020000153
3”-((5-氨基-6-氯嘧啶-4-基)氨基)-N-(3-羟基丙基)-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-唑-4-甲酰胺
按照实施例23步骤6的制备方法，用3-氨基丙-1-醇替换吗啉得白色固体，收率50.7％；m.p.189℃-192℃；1H NMR(300MHz,DMSO-d6)δ8.45(d,J＝7.2Hz,1H),8.30-8.19(m,2H),7.93-7.90(m,3H),7.72-7.69(m,2H),7.43(d,J＝8.4Hz,1H),7.26(d,J＝8.4Hz,1H),5.37(s,2H),4.49-4.47(m,1H),3.51-3.45(m,4H),2.88(s,4H),2.52-2.50(m,4H),2.27(s,3H),1.74-1.64(m,2H).HRMS(ESI):calcd.form/z C25H31ClN7O2,[M+H]+496.2222,found496.2217.HPLC(80％methanol in water):tR＝2.384min,96.63％
实施例31
Figure BDA0001978201020000161
3”-((5-氨基-6-氯嘧啶-4-基)氨基)-N-异丙基-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-甲酰胺
按照实施例23步骤6的制备方法，用丙-2-胺替换吗啉得白色固体，收率63.8％；m.p.184℃-186℃；1H NMR(300MHz,DMSO-d6)δ8.27-8.22(m,2H),7.91(d,J＝8.1Hz,2H),7.71(s,1H),7.59(d,J＝8.0Hz,2H),7.43-7.30(m,2H),7.04(d,J＝8.2Hz,1H),5.54(s,2H),4.12(s,1H),3.33(s,4H),3.07(s,4H),2.82(s,3H),1.18(s,6H).HRMS(ESI):calcd.form/z C25H30ClN7O,[M+H]+480.2279,found 480.2276.HPLC(80％methanol inwater):tR＝3.601min,96.77％.
实施例32
Figure BDA0001978201020000162
步骤1：1-(4-溴-2-硝基苯基)-4-甲基哌嗪的制备
将2-氟-5-溴硝基苯(10.0g,45.4mmol)溶在DMF(20mL)中，加入DIPEA(9.5mL,54.6mmol)和1-甲基哌嗪(6.6mL,54.6mmol)，80℃搅拌8h后，将反应液倒入100mL水中，乙酸乙酯萃取(3×100mL)，有机层用无水硫酸钠干燥，过滤，旋干得黄色固体，收率95.0％；1HNMR(300MHz,CDCl3)δ7.91(d,J＝2.4Hz,1H),7.57(dd,J＝8.8,2.4Hz,1H),7.04(d,J＝8.8Hz,1H),3.08(t,J＝4.9Hz,4H),2.58(t,J＝4.9Hz,4H),2.37(s,3H).m/z(EI-MS):300.0[M]+.
步骤2：5-溴-2-(4-甲基哌嗪-1-基)苯胺的制备
将1-(4-溴-2-硝基苯基)-4-甲基哌嗪(12.9g,43.14mmol)溶于甲醇(100mL)中，加入催化量的Pd/C,氢气保护下，室温反应2h，过滤，旋干得黄色固体，收率89％；m.p.165-167℃；1H NMR(300MHz,CDCl3)δ6.84-6.79(m,3H),4.01(s,2H),2.89(s,4H),2.45(s,4H),2.35(s,3H).m/z(EI-MS):270.0[M]+.
步骤3：N4-(5-溴-2-(4-甲基哌嗪-1-基)苯基)-6-氯嘧啶-4,5-二胺的制备
按照实施例23步骤4的制备方法，将3'-氨基-4′-(4-甲基哌嗪-1-基)-[1,1′-联苯基]-4-羧酸甲酯替换成5-溴-2-(4-甲基哌嗪-1-基)苯胺，得白色固体。收率72.5％；m.p.196-198℃；1H NMR(300MHz,CDCl3)δ8.26(s,1H),6.84-6.79(m,3H),8.10(s,1H),5.34(s,2H),2.89(s,4H),2.45(s,4H),2.34(s,3H).m/z(EI-MS):397.1[M]+.
步骤4：目标产物N4-(4′-氨基-4-(4-甲基哌嗪-1-基)-[1,1′-联苯]-3-基)-6-氯嘧啶-e-4,5-二胺的制备
将N4-(5-溴-2-(4-甲基哌嗪-1-基)苯基)-6-氯嘧啶-4,5-二胺(1.0g,2.5mmol)溶于1,4-二氧六环(30mL)中，加入4-氨基苯硼酸(2.9mmol)和碳酸铯(1.6g,5mmol)和催化量的Pd(PPh3)2Cl2，氮气保护下回流20h，过滤除去催化剂和碳酸铯，旋干滤液，柱层析分离纯化(二氯甲烷：甲醇＝50:1)得到淡黄色固体，收率67.3％；m.p.212℃-214℃；1H NMR(300MHz,DMSO-d6)δ8.16(d,J＝8.1Hz,2H),7.90(s,1H),7.65(d,J＝8.2Hz,2H),7.55(d,J＝8.4Hz,2H),7.37(d,J＝8.4Hz,1H),7.26(d,J＝8.2Hz,1H),5.43(s,2H),5.15(s,2H),3.17(s,4H),3.06(s,4H),2.75(s,3H).m/z(EI-MS):410.2[M]+.HPLC(100％methanol):tR＝7.489min,95.67％.
实施例33
Figure BDA0001978201020000171
N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)四氢-2H-吡喃-4-甲酰胺
将四氢-2H-吡喃-4-羧酸(0.35mmol)溶于DMF(8mL)中，加入BOP(0.26g,0.59mmol)和三乙胺(0.1mL,0.88mmol)，室温搅拌30min后加入实施例32(0.12g,0.29mmol)室温搅拌12h，将反应液倒入50mL水中，用乙酸乙酯(3×50mL)萃取，无水硫酸钠干燥，过滤，旋干，硅胶柱层析分离纯化(二氯甲烷：甲醇＝50:1)得白色固体，收率78.5％；m.p.207℃-209℃；1HNMR(300MHz,DMSO-d6)δ9.99(s,1H),8.21(s,1H),7.90(s,1H),7.68(dd,J＝8.4,5.9Hz,3H),7.57-7.54(m,2H),7.38-7.35(m,1H),5.38(s,2H),3.94-3.90(m,3H),3.37-3.35(m,2H),2.92(s,4H),2.76(s,4H),2.43(s,3H),1.72-1.69(m,4H).HRMS(ESI):calcd.form/zC27H32ClN7O2,[M+H]+522.2379,found 522.2377.HPLC(80％methanol in water):tR＝4.280min,95.50％.
实施例34
Figure BDA0001978201020000181
N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)-1-甲基哌啶-4-甲酰胺
按照实施例33，将四氢-2H-吡喃-4-羧酸替换成1-甲基哌啶-4-羧酸,得到白色固体，收率63.6％；m.p.157℃-160℃；1H NMR(300MHz,DMSO-d6)δ10.19(s,1H),8.22-8.19(m,2H),7.95(s,1H),7.69(d,J＝8.4Hz,2H),7.57(d,J＝8.7Hz,2H),7.36(d,J＝8.4Hz,1H),7.24(d,J＝8.1Hz,1H),5.42(s,2H),2.99-2.90(m,5H),2.85(s,4H),2.73(s,3H),2.53(s,4H),2.49(s,3H),2.03-1.99(m,4H).HRMS(ESI):calcd.form/z C28H36ClN8O,[M+H]+535.2695,found 535.2710.HPLC(80％methanol in water):tR＝4.518min,98.25％.
实施例35
Figure BDA0001978201020000182
N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)环己烷甲酰胺
按照实施例33，将四氢-2H-吡喃-4-羧酸替换成环己烷羧酸,得到白色固体，收率80.1％；m.p.256℃-258℃；1H NMR(300MHz,DMSO-d6)δ9.91(s,1H),8.18(d,J＝8.2Hz,2H),7.90(s,1H),7.69(d,J＝8.3Hz,2H),7.55(d,J＝8.4Hz,2H),7.37(d,J＝8.4Hz,1H),7.26(d,J＝8.2Hz,1H),5.43(s,2H),3.17(s,4H),3.06(s,4H),2.75(s,3H),2.34-2.30(m,1H),1.76(t,J＝12.5Hz,4H),1.42(t,J＝11.6Hz,2H),1.33-1.09(m,4H).HRMS(ESI):calcd.form/z C28H34ClN7O,[M+H]+520.2586,found 520.2584.HPLC(90％methanol inwater):tR＝4.003min,97.87％.
实施例36
Figure BDA0001978201020000183
N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)丁酰胺
按照实施例33，将四氢-2H-吡喃-4-羧酸替换成正丁酸,得到白色固体，收率79.7％；m.p.196℃-198℃；1H NMR(300MHz,DMSO-d6)δ10.00(s,1H),8.21-8.16(m,2H),7.90(d,J＝6.0Hz,1H),7.71-7.69(m,2H),7.59-7.54(m,2H),7.38(d,J＝7.8Hz,1H),7.27(d,J＝8.2Hz,1H),5.44(s,2H),3.51-3.46(m,4H),3.27-3.16(m,4H),2.88(s,3H),2.32-2.27(m,2H),1.68-1.58(m,2H),0.96-0.89(m,3H).HRMS(ESI):calcd.form/z C25H31ClN7O,[M+H]+480.2273,found 480.2274.HPLC(80％methanol in water):tR＝4.696min,96.97％.
实施例37
Figure BDA0001978201020000191
N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)苯甲酰胺
按照实施例33，将四氢-2H-吡喃-4-羧酸替换成苯甲酸,得到白色固体，收率77.9％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ10.00(s,1H),8.21-8.16(m,2H),7.90(d,J＝6.0Hz,1H),7.71-7.69(m,2H),7.59-7.54(m,2H),7.38(d,J＝7.8Hz,1H),7.27(d,J＝8.2Hz,1H),5.44(s,2H),3.51-3.46(m,4H),3.27-3.16(m,4H),2.88(s,3H),2.32-2.27(m,2H),1.68-1.58(m,2H),0.96-0.89(m,3H).HRMS(ESI):calcd.form/z C28H28ClN7O,[M+H]+514.2117,found 514.2115.HPLC(90％methanol in water):tR＝3.889min,95.09％.
实施例38
Figure BDA0001978201020000192
(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2-氟-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)(4-甲基哌嗪-1-基)甲酮
按照实施例32步骤4的制备方法，将4-氨基苯硼酸替换成2-F-4-羧基苯硼酸，得白色中间体，按照实施例23步骤6的制备方法，将吗啉替换成1-甲基哌嗪得白色固体，收率43.1％；m.p.182℃-184℃；1H NMR(300MHz,DMSO-d6)δ8.12(s,1H),7.80(s,1H),7.68-7.65(m,2H),7.60(dd,J＝7.5,2.0Hz,1H),7.10(dd,J＝7.5,2.0Hz,1H),6.93(d,J＝7.3Hz,1H),6.82(d,J＝2.0Hz,1H),5.36(s,2H),3.55(t,J＝5.1Hz,4H),3.30(t,J＝5.1Hz,4H),2.85(t,J＝4.7Hz,4H),2.53(s,4H),2.34(s,3H),2.32(s,3H).HRMS(ESI):calcd.form/zC27H32ClFN8O,[M+H]+539.2444,found 539.2443.HPLC(80％methanol in water):tR＝4.156min,95.21％.
实施例39
Figure BDA0001978201020000193
N4-(3'-氨基-4-(4-甲基哌嗪-1-基)-[1,1'-联苯]-3-基)-6-氯嘧啶电子-4,5-二胺
按照实施例32步骤4的制备方法，将4-氨基苯硼酸替换成3-氨基苯硼酸，制备得到白色固体，收率69.4％；m.p.215℃-217℃；1H NMR(300MHz,DMSO-d6)δ8.23(s,1H),8.17(s,1H),7.90(s,1H),7.23(d,J＝6.4Hz,2H),7.07(d,J＝7.7Hz,1H),6.80(s,1H),6.73(d,J＝7.6Hz,1H),6.53(d,J＝8.0Hz,1H),5.36(s,2H),5.17(s,2H),2.85(s,4H),2.61(s,4H),2.25(s,3H).HRMS(ESI):calcd.form/z C21H24ClN7,[M+H]+410.1854,found410.1852.HPLC(100％methanol):tR＝7.491min,95.66％.
实施例40
Figure BDA0001978201020000201
N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-4”-(4-甲基哌嗪-1-基)-[1,1′-联苯]-3-基)四氢-2H-吡喃-4-甲酰胺
按照实施例33的制备方法，将实施例32替换成实施例39，得到白色固体，收率65.0％；m.p.212℃-214℃；1H NMR(300MHz,DMSO-d6)δ9.99(s,1H),8.24(s,1H),8.19(s,1H),7.89(s,2H),7.59(d,J＝8.0Hz,1H),7.44-7.19(m,4H),5.38(s,2H),3.91(d,J＝10.9Hz,2H),3.47-3.35(m,3H),2.86(s,4H),2.54(m,4H),2.24(s,3H),1.70(s,4H).HRMS(ESI):calcd.form/z C27H32ClN7O2,[M+H]+522.2379,found 522.2368.HPLC(100％methanol):tR＝7.105min,98.72％.
实施例41
Figure BDA0001978201020000202
N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-3-基)-1-甲基哌啶-4-甲酰胺
按照实施例34的制备方法，将实施例32替换成实施例39，得到白色固体，收率56.9％；m.p.158℃-160℃；1H NMR(300MHz,DMSO-d6)δ9.95(s,1H),8.24(s,1H),8.18(s,1H),7.89(s,2H),7.59(d,J＝8.3Hz,1H),7.39-7.19(m,4H),5.38(s,2H),2.86-2.83(m,4H),2.80(s,1H),2.57-2.51(m,4H),2.22(s,3H),2.15(s,3H),1.89-1.82(m,2H),1.79-1.58(m,4H),1.22(s,2H).HRMS(ESI):calcd.form/z C28H36ClN8O,[M+H]+535.2695,found535.2702.HPLC(100％methanol):tR＝7.252min,95.45％.
实施例42
Figure BDA0001978201020000203
6-氯-N4-(4′-甲氧基-4-(4-甲基哌嗪-1-基)-[1,1′-联苯]-3-基)嘧啶-4,5-二胺
按照实施例32步骤4的制备方法，将4-氨基苯硼酸替换成4-甲氧基苯硼酸，得到白色固体，收率59.9％；m.p.211℃-213℃；1H NMR(300MHz,DMSO-d6)δ8.24(s,2H),7.90(s,1H),7.57(d,J＝7.9Hz,2H),7.40-7.35(m,3H),7.24(d,J＝8.3Hz,1H),5.37(s,2H),5.22(s,1H),4.52(s,2H),2.85(t,J＝4.5Hz,4H),2.53(s,4H),2.24(s,3H).m/z(EI-MS):425.2[M]+.HPLC(80％methanol in water):tR＝4.590min,99.44％.
实施例43
Figure BDA0001978201020000211
6-氯-N4-(5-(呋喃-3-基)-2-(4-甲基哌嗪-1-基)苯基)嘧啶-4,5-二胺
按照实施例32步骤4的制备方法，将4-氨基苯硼酸替换成3-呋喃苯硼酸，得到白色固体，收率70.1％；m.p.164℃-166℃；1H NMR(300MHz,DMSO-d6)δ8.23(s,1H),7.90(s,1H),7.54(d,J＝7.5Hz,1H),7.43(s,1H),7.07(d,J＝7.7Hz,1H),6.91(d,J＝7.4Hz,1H),6.82(s,1H),6.53(d,J＝8.0Hz,1H),5.36(s,2H),2.85(s,4H),2.61(s,4H),2.25(s,3H).HRMS(ESI):calcd.form/z C19H22ClN6O,[M+H]+385.1538,found 385.1538.HPLC(90％methanolin water):tR＝6.859min,96.26％.
实施例44
Figure BDA0001978201020000212
6-氯-N4-(2-(4-甲基哌嗪-1-基)-5-(嘧啶-5-基)苯基)嘧啶-4,5-二胺
按照实施例32步骤4的制备方法，将4-氨基苯硼酸替换成4-嘧啶苯硼酸，得到白色固体，收率45.8％；m.p.189℃-191℃；1H NMR(300MHz,DMSO-d6)δ9.17(s,1H),9.10(s,2H),8.57(s,1H),7.80(s,1H),7.10(dd,J＝7.5,2.0Hz,1H),6.99(d,J＝7.4Hz,1H),6.82(d,J＝2.0Hz,1H),5.32(s,2H),2.85(s,4H),2.54(s,4H),2.34(s,3H).HRMS(ESI):calcd.form/zC19H22ClN8,[M+H]+397.1651,found 397.1653.HPLC(80％methanol in water):tR＝3.973min,97.50％.
实施例45
Figure BDA0001978201020000213
6-氯-N4-(2-(4-甲基哌嗪-1-基)-5-(吡啶-4-基)苯基)嘧啶-4,5-二胺
按照实施例32步骤4的制备方法，将4-氨基苯硼酸替换成4-吡啶苯硼酸，得到白色固体，收率44.2％；m.p.202℃-204℃；1H NMR(300MHz,DMSO-d6)δ8.83(s,1H),8.69(d,J＝5.1Hz,2H),7.80(s,1H),7.75(s,2H),7.10(dd,J＝7.5,2.0Hz,1H),6.94(d,J＝7.5Hz,1H),6.82(s,1H),5.54(s,2H),3.30(t,J＝5.1Hz,4H),2.85(t,J＝4.7Hz,4H),2.54(s,4H),2.34(s,3H),2.32(s,3H).m/z(EI-MS):411.1[M]+.HPLC(100％methanol):tR＝7.074min,96.00％.
实施例46
Figure BDA0001978201020000221
1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-羧酸甲酯步骤1：4-(4-甲基哌嗪-1-基)-3-硝基苯胺的制备
将4-F-3-硝基苯胺(5g,32mmol)溶解在乙腈(50mL)中，加入DIPEA(7.9mL,47.8mmol)和1-甲基哌嗪(5.3mL,67.8mmol)，回流12h，将反应液旋干得红色固体粗品，用乙腈洗涤，抽滤，烘干，收率95.5％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ7.06(d,J＝8.6Hz,1H),6.76(s,1H),6.69(d,J＝8.5Hz,1H),5.34(s,2H),2.70(t,J＝4.4Hz,4H),2.27(s,4H),2.09(s,3H).m/z(EI-MS):237.1[M]+.
步骤2：1-(4-叠氮基-2-硝基苯基)-4-甲基哌嗪的制备
将4-(4-甲基哌嗪-1-基)-3-硝基苯胺(5.0g,21.25mmol)溶在2M的HCl中，冰浴条件下滴加NaNO2(2.2g,31.8mmol)的水溶液(12mL)，在冰浴条件下搅拌30min，加入叠氮化钠(2.8g,42.5mmol)，升至室温搅拌2h，反应液用2M的NaOH调节至pH＝9～10至红棕色固体析出，过滤干燥，收率87.7％；m.p.88-91℃；1H NMR(300MHz,DMSO-d6)δ7.48(d,J＝2.2Hz,1H),7.34-7.20(m,2H),2.85(t,J＝4.7Hz,4H),2.31(t,J＝4.8Hz,4H),2.11(s,3H).m/z(EI-MS):262.1[M]+.
步骤3：1-(4-(4-甲基哌嗪-1-基)-3-硝基苯基)-1H-1,2,3-三唑-4-羧酸甲酯的制备
将1-(4-叠氮基-2-硝基苯基)-4-甲基哌嗪(2.0g,7.6mmol)溶解在甲醇(50mL)加入丙炔酸甲酯(1.8g,22.8mmol)，随后加入CuI(0.14g,0.76mmol)和DIPEA(1.2mL,7.6mmol)回流48h。过滤除去CuI，滤液旋干得粗品，用乙酸乙酯洗涤得红棕色固体。收率61.7％；m.p.159-161℃；1H NMR(300MHz,DMSO-d6)δ9.45(s,1H),8.36(d,J＝2.7Hz,1H),8.11-8.01(m,1H),7.42(d,J＝9.1Hz,1H),3.80(s,3H),2.99(t,J＝5.4Hz,4H),2.35(t,J＝5.2Hz,4H),2.13(s,3H).m/z(EI-MS):369.2[M+Na]+.
步骤4：1-(3-氨基-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-羧酸甲酯的制备
将1-(4-(4-甲基哌嗪-1-基)-3-硝基苯基)-1H-1,2,3-三唑-4-羧酸甲酯(1.7g,4.9mmol)溶在甲醇(50mL)中，加入催化量的Pd/C，氢气保护下室温搅拌6h，过滤除去Pd/C，滤液旋干得粉色固体。收率85.3％；m.p.194-197℃；1H NMR(300MHz,DMSO-d6)δ9.28(s,1H),7.28(d,J＝1.9Hz,1H),7.07(d,J＝1.9Hz,2H),5.15(s,2H),3.90(s,3H),2.87(t,J＝4.5Hz,4H),2.53(br s,4H),2.26(s,3H).m/z(EI-MS):317.2[M]+.
步骤5：目标产物1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-羧酸甲酯的制备
按照实施例23的步骤4的制备方法，将3'-氨基-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸甲酯替换成1-(3-氨基-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-羧酸甲酯，得米白色固体，收率65.9％；m.p.231℃-233℃；1H NMR(300MHz,DMSO-d6)δ9.46(s,1H),8.62(s,1H),8.34(s,1H),7.95(s,1H),7.64(d,J＝8.6Hz,1H),7.37(d,J＝8.7Hz,1H),5.44(s,2H),3.89(s,3H),2.88(s,4H),2.51(s,4H),2.23(s,3H).HRMS(ESI):calcd.form/zC19H22ClFN9O2,[M+H]+444.1657,found 444.1660.HPLC(90％methanol in water):tR＝3.775min,97.63％.
实施例47
Figure BDA0001978201020000231
(1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-基)(吗啉代)甲酮
步骤1：1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-羧酸的制备
按照实施例23步骤5的制备方法，将3′-((5-氨基-6-氯嘧啶-4-基)氨基)-4′-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸甲酯替换成1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-羧酸甲酯，得米白色固体，收率87.6％；m.p.232℃-234℃；1H NMR(300MHz,DMSO-d6)δ12.20(s,1H),9.36(s,1H),8.62(s,1H),8.34(s,1H),7.95(s,1H),7.63(d,J＝8.7Hz,1H),7.38(d,J＝8.7Hz,1H),5.47(s,2H),2.90(s,4H),2.53(s,4H),2.34(s,3H).HRMS(ESI):calcd.form/z C18H20ClFN9O2,[M+H]+430.1488,found 430.1492.HPLC(90％methanol in water):tR＝3.548min,99.16％.
步骤2：目标产物(1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-基)(吗啉代)甲酮的制备
按照实施例23步骤6的制备方法，将3'-((5-氨基-6-氯嘧啶-4-基)氨基)-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸替换成1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-羧酸，得到米白色固体。收率68.3％；m.p.200℃-202℃；1H NMR(300MHz,DMSO-d6)δ9.20(s,1H),8.60(s,1H),8.53(t,J＝5.8Hz,1H),8.34(s,1H),7.94(s,1H),7.62(d,J＝8.7Hz,1H),7.37(d,J＝8.6Hz,1H),5.45(s,2H),3.58(t,J＝4.5Hz,4H),3.45-3.36(m,4H),2.91(t,J＝4.5Hz,4H),2.60(s,4H),2.44(s,4H),2.30(s,3H).HRMS(ESI):calcd.form/z C24H32ClFN11O2,[M+H]+542.2502,found542.2500.HPLC(80％methanol in water):tR＝4.612min,99.65％.
实施例48
Figure BDA0001978201020000241
1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-N-(3-吗啉代丙基)-1H-1,2,3-三唑-4-甲酰胺
按照实施例24的制备方法，将3'-((5-氨基-6-氯嘧啶-4-基)氨基)-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸替换成1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-羧酸，得到米白色固体。收率65.9％；m.p.203℃-205℃；1H NMR(300MHz,DMSO-d6)δ9.19(s,1H),8.82(t,J＝5.6Hz,1H),8.59(s,1H),8.34(s,1H)7.94(s,1H),7.62(d,J＝8.7Hz,1H),7.36(d,J＝8.7Hz,1H),5.45(s,2H),3.61(s,4H),3.36-3.33(m,4H),2.90(s,4H),2.58(s,4H),2.40(s,4H),2.28(s,3H),1.73-1.68(m,2H).HRMS(ESI):calcd.form/z C25H34ClFN11O2,[M+H]+556.2660,found 556.2662.HPLC(80％methanol in water):tR＝4.457min,98.27％.
实施例49
Figure BDA0001978201020000242
(1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-基)(4-甲基哌嗪-1-基)甲酮
按照实施例25的制备方法，将3'-((5-氨基-6-氯嘧啶-4-基)氨基)-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸替换成1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-羧酸，得到米白色固体。收率46.2％；m.p.225℃-228℃；1H NMR(300MHz,DMSO-d6)δ9.19(s,1H),8.72(s,1H),8.52(s,1H),8.34(s,1H)7.94(s,1H),7.62(d,J＝8.7Hz,1H),7.37(d,J＝8.7Hz,1H),5.45(s,2H),3.76(s,4H),3.39(s,4H),2.93(s,4H),2.68(s,4H)2.22(s,3H),2.15(s,3H).HRMS(ESI):calcd.form/zC23H31ClFN11O,[M+H]+512.2396,found 512.2397.HPLC(90％methanol in water):tR＝3.707min,98.00％.
实施例50
Figure BDA0001978201020000243
1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-N,N-二甲基-1H-1,2,3-三唑-4-甲酰胺
按照实施例27的制备方法，将3'-((5-氨基-6-氯嘧啶-4-基)氨基)-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸替换成1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-羧酸，得到米白色固体。收率66.6％；m.p.215℃-217℃；1H NMR(300MHz,DMSO-d6)δ9.84(s,1H),9.18(s,1H),8.62(s,1H),8.27(s,1H)7.95(s,1H),7.68(s,1H),7.44(s,1H),5.52(s,2H),3.58(s,4H),3.30(s,6H),3.04(s,4H),2.88(s,3H).HRMS(ESI):calcd.form/z C20H25ClFN10O,[M+H]+457.1974,found 457.1966.HPLC(80％methanol in water):tR＝4.203min,98.52％.
实施例51
Figure BDA0001978201020000251
1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-N,N-二甲基-1H-1,2,3-三唑-4-甲酰胺
按照实施例26的制备方法，将3'-((5-氨基-6-氯嘧啶-4-基)氨基)-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸替换成1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-羧酸，得到米白色固体。收率66.6％；m.p.215℃-217℃；1H NMR(300MHz,DMSO-d6)δ9.84(s,1H),9.18(s,1H),8.62(s,1H),8.27(s,1H)7.95(s,1H),7.68(s,1H),7.44(s,1H),5.52(s,2H),3.58(s,4H),3.30(s,6H),3.04(s,4H),2.88(s,3H).HRMS(ESI):calcd.form/z C20H25ClFN10O,[M+H]+457.1974,found 457.1966.HPLC(80％methanol in water):tR＝4.203min,98.52％.
实施例52
Figure BDA0001978201020000252
1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-N-(2-(二甲基氨基)乙基)-1H-1,2,3-三唑-4-甲酰胺
按照实施例28的制备方法，将3′-((5-氨基-6-氯嘧啶-4-基)氨基)-4′-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸替换成1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-羧酸，得到米白色固体。收率39.9％；m.p.149℃-152℃；1H NMR(300MHz,DMSO-d6)δ9.84(s,1H),9.18(s,1H),8.62(s,1H),8.54(s,1H),7.95(s,1H),7.68(d,J＝8.7Hz,1H),7.44(d,J＝8.7Hz,1H),5.46(s,2H),3.08-2.90(m,6H),2.77(s,6H),2.50(s,4H),1.90(s,4H),1.28-1.23(m,2H).HRMS(ESI):calcd.form/zC22H30ClFN11O,[M+H]+500.2402,found 500.2404.HPLC(80％methanol in water):tR＝4.157min,98.88％.
实施例53
Figure BDA0001978201020000261
1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-N-(2-(吡咯烷-1-基)乙基)-1H-1,2,3-三唑-4-甲酰胺
按照实施例29的制备方法，将3'-((5-氨基-6-氯嘧啶-4-基)氨基)-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸替换成1-(3-((5-氨基-6-氯嘧啶-4-基)氨基)-4-(4-甲基哌嗪-1-基)苯基)-1H-1,2,3-三唑-4-羧酸，得到米白色固体。收率40.7％；m.p.172℃-175℃；1H NMR(300MHz,DMSO-d6)δ9.19(s,1H),8.72(s,1H),8.52(s,1H),8.34(s,1H)7.94(s,1H),7.62(d,J＝8.7Hz,1H),7.37(d,J＝8.7Hz,1H),5.45(s,2H),3.64-3.62(m,2H),3.38-3.34(m,6H),3.12(s,4H),2.54(s,2H),2.48(s,2H),2.36(s,3H),1.93(s,4H).HRMS(ESI):calcd.form/z C24H32ClFN11O,[M+H]+526.2553,found 526.2543.HPLC(80％methanol in water):tR＝4.211min,99.19％.
实施例54
Figure BDA0001978201020000262
3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-N，N-二甲基-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-甲酰胺
步骤1：1-溴-2,4-二氟-3-硝基苯的制备：
在冰浴条件下制备硫酸(10mL)与三氟醋酸(50mL)的混合溶液,加入2,6-二氟硝基苯(5.0g,31.4mmol)，分批缓慢加入N-溴代丁二酰亚胺(6.15g,34.5mmol)，反应液在室温下搅拌18h，将反应液倒入冰水(100mL)，乙酸乙酯(3×50mL)萃取，有机层用2M氢氧化钠洗涤，无水硫酸钠干燥，过滤，旋干，得红色油状物(6.6g)，产率90.0％；1H NMR(300MHz,CDCl3)δ7.78(m,1H),7.28-7.16(m,1H).m/z(EI-MS):237.9[M]+
步骤2：2'，4'-二氟-3'-硝基-[1,1'-联苯]-4-羧酸甲酯的制备：
按照实施例23步骤1的制备方法将4-溴1-F硝基苯替换为1-溴-2,4-二氟-3-硝基苯。收率65.0％.1H NMR(300MHz,CDCl3)δ7.98-7.96(m,2H),7.91-7.87(m,1H),7.58-7.55(m,2H),7.19-7.15(m,1H),3.95(s,3H).m/z(EI-MS):294.1[M]+.
步骤3：2'-氟-4'-(4-甲基哌嗪-1-基)-3'-硝基-[1,1'-联苯基]-4-羧基甲酸甲酯的制备：
按照实施例23步骤2的制备方法将4'-氟-3'-硝基-[1,1'-联苯基]-4-羧酸甲酯替换为2'，4'-二氟-3'-硝基-[1,1'-联苯]-4-羧酸甲酯。收率88.2％；m.p.112℃-115℃；1HNMR(300MHz,DMSO-d6)δ8.02-7.99(m,2H),7.69-7.62(m,3H),6.98(d,J＝8.6Hz,1H),3.95(s,3H),3.39(t,J＝4.7Hz,4H),2.54(t,J＝4.6Hz,4H),2.34(s,3H).m/z(EI-MS):374.1[M]+.
步骤4：3'-氨基-2'-氟-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸甲酯的制备：
按照实施例23步骤3的制备方法将4'-(4-甲基哌嗪-1-基)-3'-硝基-[1,1'-联苯]-4-羧酸甲酯替换为2'-氟-4'-(4-甲基哌嗪-1-基)-3'-硝基-[1,1'-联苯基]-4-羧基甲酸甲酯。收率73.5％；m.p.162℃-165℃；1H NMR(300MHz,DMSO-d6)δ8.01-7.99(m,2H),7.68-7.66(m,2H),6.75(dd,J＝7.5,5.7Hz,1H),6.58(d,J＝7.5Hz,1H),4.35(s,2H),3.95(s,3H),3.39(t,J＝4.7Hz,4H),2.54(t,J＝4.7Hz,4H),2.34(s,3H).m/z(EI-MS):344.2[M]+.步骤5：3′-((5-氨基-6-氯嘧啶-4-基)氨基)-2′-氟-4′-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸甲酯的制备：
按照实施例23步骤4的制备方法将3'-氨基-4′-(4-甲基哌嗪-1-基)-[1,1′-联苯]-4-羧酸甲酯替换为3′-氨基-2′-氟-4′-(4-甲基哌嗪-1-基)-[1,1′-联苯]-4-羧酸甲酯。收率55.7％；m.p.222℃-225℃；1H NMR(300MHz,DMSO-d6)δ8.11(s,1H),8.01-7.99(m,2H),7.80(s,1H),7.62-7.60(m,2H),7.12(dd,J＝7.5,5.7Hz,1H),6.65(d,J＝7.5Hz,1H).5.35(s,2H),3.95(s,3H),3.34(t,J＝4.7Hz,4H),2.57(t,J＝4.7Hz,4H),2.39(s,3H).HRMS(ESI):calcd.form/z C23H24ClFN6O2,[M+H]+471.1706,found 471.1707.HPLC(80％methanol in water):tR＝2.744min,99.52％.
步骤6：3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸的制备：
按照实施例23步骤5的制备方法将3'-((5-氨基-6-氯嘧啶-4-基)氨基)-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸甲酯替换为3'-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸甲酯。两步收率80.4％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ8.11(dd,J＝5.3,2.2Hz,3H),7.80(s,1H),7.69-7.67(m,2H),7.12(dd,J＝7.5,5.7Hz,1H),6.66(d,J＝7.5Hz,1H),5.35(s,2H),3.93(s,3H),3.34(t,J＝4.7Hz,4H),2.57(s,4H),2.32(s,3H).m/z(EI-MS):457.2[M]+.
步骤7：目标产物3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-N，N-二甲基-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-甲酰胺的制备：
按照实施例23步骤6类似的制备方法。收率77.5％；m.p.158℃-160℃；1H NMR(300MHz,DMSO-d6)δ8.03(s,1H),7.71(s,1H),7.60-7.46(m,4H),7.40(t,J＝8.5Hz,1H),7.00(d,J＝8.6Hz,1H),5.49(s,2H),2.99-2.98(m,6H),2.87(s,4H),2.38(s,4H),2.18(s,3H).HRMS(ESI):calcd.form/z C24H27ClFN7O,[M+H]+484.2202,found 484.2203.HPLC(80％methanol in water):tR＝3.448min,95.30％.
实施例55：
Figure BDA0001978201020000281
(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)(吗啉代)甲酮
按照实施例54的制备方法将二甲基胺替换为吗啉，收率84.7％；m.p.145℃-148℃；1H NMR(300MHz,DMSO-d6)δ8.05(s,1H),7.72(s,1H),7.54(dd,J＝8.5,5.4Hz,4H),7.41(t,J＝8.5Hz,1H),7.03(d,J＝8.6Hz,1H),5.48(s,2H),3.61(s,4H),3.34(s,4H),2.98(s,4H),2.65(s,4H),2.38(s,3H).HRMS(ESI):calcd.form/z C26H29ClFN7O2,[M+H]+526.2128,found 526.2122.HPLC(80％methanol in water):tR＝3.560min,98.66％
实施例56
Figure BDA0001978201020000282
3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-N-(2-吗啉代乙基)-[1,11,1'-联苯基]-4-甲酰胺
按照实施例54的制备方法将二甲基胺替换为2-吗啉乙基-1-胺，收率74.9％；m.p.199℃-202℃；1H NMR(300MHz,DMSO-d6)δ8.48(t,J＝5.5Hz,1H),8.09(s,1H),7.90(d,J＝8.1Hz,2H),7.71(s,1H),7.59(d,J＝7.9Hz,2H),7.41(t,J＝8.5Hz,1H),7.00(d,J＝8.5Hz,1H),5.50(s,2H),3.57(s,4H),3.41-3.38(m,2H),2.91(s,4H),2.49(s,4H),2.42(s,6H),2.21(s,3H).HRMS(ESI):calcd.form/z C28H34ClFN8O2,[M+H]+569.2550,found569.2548.HPLC(80％methanol in water):tR＝3.634min,98.88％.
实施例57
Figure BDA0001978201020000283
3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-N-(3-吗啉代丙基)-[1,11,1'-联苯基]-4-甲酰胺
按照实施例54的制备方法将二甲基胺替换为3-吗啉丙基-1-胺，收率65.2％；m.p.202℃-205℃；1H NMR(300MHz,DMSO-d6)δ8.46(t,J＝5.7Hz,1H),7.96(s,1H),7.81(d,J＝8.2Hz,2H),7.31(t,J＝8.6Hz,2H),6.90(d,J＝8.7Hz,1H),5.40(s,2H),3.47(t,J＝5.4Hz,4H),3.21-3.19(m,2H),2.80(s,4H),2.28-2.22(m,10H),2.09(s,3H),1.60(t,J＝7.1Hz,2H).HRMS(ESI):calcd.form/z C29H37ClFN8O2,[M+H]+583.2706,found583.2707.HPLC(80％methanol in water):tR＝3.601min,97.46％.
实施例58
Figure BDA0001978201020000291
(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)(4-乙基哌嗪-1-基)甲酮
按照实施例54的制备方法将二甲基胺替换为1-乙基哌嗪，收率64.8％；m.p.229℃-232℃；1H NMR(300MHz,DMSO-d6)δ8.05(s,1H),7.71(s,1H),7.57(d,J＝8.2Hz,2H),7.47(d,J＝8.1Hz,2H),7.39(t,J＝8.5Hz,2H),7.00(d,J＝8.7Hz,1H),5.49(s,2H),3.61(s,2H),2.91(s,4H),2.38-2.34(m,10H),2.20(s,3H),1.17(t,J＝7.1Hz,2H),1.01(t,J＝7.1Hz,2H).HRMS(ESI):calcd.form/z C28H34ClFN8O,[M+H]+553.2587,found553.2596.HPLC(80％methanol in water):tR＝3.794min,97.08％.
实施例59
Figure BDA0001978201020000292
N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2′-氟-4”-(4-甲基哌嗪-1-基)-[1,1′-联苯]--4-基)四氢-2H-吡喃-4-甲酰胺
步骤1：2'，4'-二氟-3'-硝基[1,1′-联苯]-4-胺的制备
按照实施例23步骤1的制备方法将4-溴1-F硝基苯替换为1-溴-2,4-二氟-3-硝基苯，收率69.0％；m.p.136℃-138℃；1H NMR(300MHz,DMSO-d6)δ7.87-7.83(m,1H),7.24-7.22(m,2H),7.15(dd,J＝9.0,7.5Hz,1H),6.72-6.70(m,2H),5.24(s,2H).m/z(EI-MS):251.1[M]+.
步骤2：2'-氟-4'-(4-甲基哌嗪-1-基)-3'-硝基[1,1'-联苯]-4-胺的制备
按照实施例23步骤2的制备方法将4'-氟-3'-硝基-[1,1'-联苯基]-4-羧酸甲酯替换为2'，4'-二氟-3'-硝基[1,1'-联苯]-4-胺，收率88.2％；m.p.145℃-147℃；1H NMR(300MHz,DMSO-d6)δδ7.60(dd,J＝7.4,5.8Hz,1H),7.25–7.18(m,2H),6.96(d,J＝7.5Hz,1H),6.77–6.71(m,2H),5.24(s,2H),3.20(t,J＝4.6Hz,4H),2.54(t,J＝4.6Hz,4H),2.34(s,3H).m/z(EI-MS):331.2[M]+.
步骤3：N-(2'-氟-4'-(4-甲基哌嗪-1-基)-3'-硝基[1,1'-联苯]-4-基)四氢-2H-吡喃-4-甲酰胺的制备：
按照实施例33类似的制备方法，将N4-(4'-氨基-4-(4-甲基哌嗪-1-基)-[1,1'-联苯]-3-基)-6-氯嘧啶-e-4,5-二胺替换为2'-氟-4'-(4-甲基哌嗪-1-基)-3'-硝基[1,1'-联苯]-4-胺，收率88.2％；m.p.166℃-168℃；1H NMR(300MHz,DMSO-d6)δ9.52(s,1H),7.63(dd,J＝7.5,5.7Hz,1H),7.42-7.38(m,4H),6.99(d,J＝7.5Hz,1H),3.95-3.92(m,2H),3.53-3.50(m,2H),3.20(t,J＝4.7Hz,4H),2.54(t,J＝4.7Hz,4H),2.65-2.60(m,4H),2.08-2.01(m,2H),1.83-1.76(m,2H).m/z(EI-MS):443.2[M]+.
步骤4：目标产物N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]--4-基)四氢-2H-吡喃-4-甲酰胺的制备
按照实施例23步骤3和步骤4类似的制备方法，得到化合物59，三步收率36.6％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ9.56(s,1H),8.25(s,1H),7.80-7.77(m,3H),7.41-7.39(m,2H),7.07(dd,J＝7.5,5.7Hz,1H),6.68(d,J＝7.3Hz,1H),5.43(s,2H),3.52-3.49(m,4H),3.34(t,J＝4.6Hz,4H),2.70-2.67(m,1H),2.44(s,4H),2.22(s,3H),2.06-1.99(m,2H),1.85-1.78(m,2H)..HRMS(ESI):calcd.form/z C27H31ClFN7O2,[M+H]+540.2285,found540.2276.HPLC(90％methanol in water):tR＝3.656min,98.94％.
实施例60
Figure BDA0001978201020000301
N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-吡啶-4-基)-1-甲基哌啶-4-甲酰胺
步骤1：N-(2'-氟-4'-(4-甲基哌嗪-1-基)-3'-硝基[1,1'-联苯]-4-基)-1-甲基哌啶-4-甲酰胺的制备
按照实施例59步骤3的制备方法，将四氢吡喃-4-甲酸替换成1-甲基哌嗪-4-甲酸，收率75.3％；m.p.170℃-172℃；1H NMR(300MHz,DMSO-d6)δ9.55(s,1H),7.63(dd,J＝7.5,5.7Hz,1H),7.40(s,4H),6.98(d,J＝7.5Hz,1H),3.22(t,J＝4.7Hz,4H),2.99-2.93(m,6H),2.64-2.58(m,4H),2.37(s,3H),2.29-2.24(m,2H),2.09-2.02(m,2H),1.71-1.64(m,2H).m/z(EI-MS):455.2[M]+.
步骤2：目标产物N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-吡啶-4-基)-1-甲基哌啶-4-甲酰胺的制备：
按照实施例23步骤3和步骤4类似的制备方法，得到化合物60，三步收率35.3％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ9.66(s,1H),8.18(s,1H),7.80(s,1H),7.63(d,J＝7.5,2H),7.40(d,J＝7.6,2H),7.08-7.05(m,1H),6.61(d,J＝7.5Hz,1H),5.30(s,2H),3.20(t,J＝4.9Hz,4H),3.01-2.96(m,6H),2.63-2.60(m,4H),2.37(s,3H),2.21-2.18(m,4H),2.07-2.02(m,4H).HRMS(ESI):calcd.form/z C28H34ClFN8O,[M+H]+553.2607,found553.2606.HPLC(80％methanol in water):tR＝3.168min,97.33％.
实施例61
Figure BDA0001978201020000311
N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2′-氟-4”-(4-甲基哌嗪-1-基)-[1,1′-联苯]-哌啶-4-基)-2-(四氢-2H-吡喃-4-基)乙酰胺
步骤1：N-(2'-氟-4'-(4-甲基哌嗪-1-基)-3′-硝基[1,1′-联苯]-4-基)-2-(四氢-2H-吡喃-4-基)乙酰胺的制备
按照实施例59步骤3，四氢吡喃-4-甲酸替换成四氢吡喃-4-乙酸，收率68.9％；m.p.148℃-150℃；1H NMR(300MHz,DMSO-d6)δ7.80-7.77(m,2H),7.70(s,1H),7.65-7.63(m,1H),7.39(d,J＝7.5Hz,2H),6.94(d,J＝7.5Hz,1H),3.90-3.87(m,2H),3.55-3.51(m,2H),3.24(t,J＝4.7Hz,4H),,2.60(s,3H),2.38(t,J＝4.7Hz,4H),2.15(d,J＝7.0Hz,2H),2.05-1.99(m,1H),1.20-1.17(m,4H).m/z(EI-MS):457.2[M]+.
步骤2：目标产物N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2′-氟-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-哌啶-4-基)-2-(四氢-2H-吡喃-4-基)乙酰胺的制备
按照实施例23步骤3和步骤4类似的制备方法，得到化合物61，三步收率38.6％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ8.24(s,1H),8.11(s,1H),7.80(s,1H),7.40(s,4H),7.15-7.12(m,1H),6.73(d,J＝7.5Hz,1H),5.42(s,2H),3.55-3.50(m,4H),3.53(t,J＝4.6Hz,4H),2.48(s,4H),2.26(s,3H),2.15(d,J＝7.0Hz,2H),2.03-2.01(m,1H),1.70-1.64(m,4H).HRMS(ESI):calcd.form/z C28H33ClFN7O2,[M+H]+554.2441,found554.2440.HPLC(80％methanol in water):tR＝3.524min,99.10％.
实施例62
Figure BDA0001978201020000312
2-氨基-N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2′-氟-4”-(4-甲基哌嗪-1-基)-[1,1′联苯基]-4-基)-3-甲基丁酰胺
步骤1：(1-((2'-氟-4′-(4-甲基哌嗪-1-基)-3′-硝基-[1,1′-联苯]-4-基)氨基)-3-甲基叔丁基-1-氧代丁-2-基)氨基甲酸的制备
按照实施例59步骤3，将四氢吡喃-4-甲酸替换成(叔丁氧羰基)缬氨酸，收率69.0％；m.p.108℃-110℃；1H NMR(300MHz,DMSO-d6)δ9.63(s,1H),7.64-7.61(m,3H),7.44-7.42(m,2H),7.39(s,3H),6.98(d,J＝7.5Hz,1H),4.13-4.12(m,1H),3.75-3.72(m,2H),3.31-3.27(m,2H),2.79-2.77(m,2H),2.63-2.61(m,1H),2.60(s,3H),2.24-2.22(m,2H),1.44(s,9H),0.94-0.88(m,6H).m/z(EI-MS):530.3[M]+.
步骤2：目标产物2-氨基-N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1′联苯基]-4-基)-3-甲基丁酰胺的制备
按照实施例23步骤3和步骤4类似的制备方法，得到化合物62，三步收率46.9％,m.p.189℃-192℃；1H NMR(300MHz,DMSO-d6)δ8.00(s,1H),7.74-7.71(m,3H),7.45(s,2H),7.33(t,J＝8.5Hz,1H),6.96(d,J＝7.2Hz,1H),5.47(s,2H),3.15-3.12(m,1H),2.86(s,4H),2.36(s,4H),2.16(s,3H),1.95(s,2H),1.17(s,1H),0.93(s,3H),0.86(s,3H).HRMS(ESI):calcd.form/z C26H32ClFN8O,[M+H]+527.2444,found 527.2449.HPLC(80％methanolin water):tR＝3.858min,99.62％.
实施例63
Figure BDA0001978201020000321
2-氨基-N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1'联苯基]-4-基)-4-甲基戊酰胺
步骤1：(1-((2'-氟-4'-(4-甲基哌嗪-1-基)-3'-硝基-[1,1'-联苯]-4-基)氨基)-4-甲基叔丁基-1-氧代戊-2-基)氨基甲酸的制备
按照实施例59步骤3，将四氢吡喃-4-甲酸替换成(叔丁氧羰基)亮氨酸，收率67.2％；m.p.114℃-116℃；1H NMR(300MHz,DMSO-d6)δ9.46(s,1H),7.65-7.62(m,1H),7.45-7.42(m,4H),6.95(d,J＝7.5Hz,1H),6.24(s,1H),4.04-4.01(m,1H),3.87-3.82(m,2H),3.31-3.25(m,2H),2.79-2.74(m,2H),2.25-2.19(m,4H),1.98-1.92(m,2H),1.71-1.65(m,1H),1.44(s,9H),0.96-0.90(m,6H).m/z(EI-MS):544.3[M]+.
步骤2：目标产物2-氨基-N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1'联苯基]-4-基)-4-甲基戊酰胺的制备
按照实施例23步骤3和步骤4类似的制备方法，得到化合物63，三步收率47.6％；m.p.182℃-185℃；1H NMR(300MHz,DMSO-d6)δ7.99(s,1H),7.73-7.71(m,3H),7.45(d,J＝8.1Hz,2H),7.33(t,J＝8.5Hz,2H),6.96(d,J＝8.6Hz,2H),5.45(s,2H),3.38-3.36(m,1H),2.87(s,4H),2.36(s,4H),2.17(s,3H),1.78-1.74(m,2H),1.52-1.47(m,2H),1.19-1.17(m,1H),0.90(t,J＝7.2Hz,6H).m/z(EI-MS):541.3[M]+.HPLC(80％methanol in water):tR＝3.680min,98.32％.
实施例64
Figure BDA0001978201020000331
2-氨基-N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1'联苯基]-4-基)乙酰胺
步骤1：(2-((2'-氟-4'-(4-甲基哌嗪-1-基)-3'-硝基-[1,1'-联苯]-4-基)氨基)-2-氧代乙基叔丁基)氨基甲酸酯的制备
按照实施例59步骤3，将四氢吡喃-4-甲酸替换成(叔丁氧羰基)甘氨酸，收率70.0％；m.p.112℃-114℃；1H NMR(300MHz,DMSO-d6)δ8.20(s,1H),7.63(dd,J＝7.5,5.7Hz,1H),7.49-7.47(m,2H),7.44-7.42(m,2H),6.94(d,J＝7.5Hz,1H),6.31(s,1H),3.89(s,2H),3.30(t,J＝4.7Hz,4H),2.44(s,4H),2.24(s,3H),1.44(s,9H).m/z(EI-MS):486.2[M]+.
步骤2：目标产物2-氨基-N-(3”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1'联苯基]-4-基)乙酰胺的制备
按照实施例23步骤3和步骤4类似的制备方法，得到化合物64，三步收率50.9％；m.p.177℃-179℃；1H NMR(300MHz,DMSO-d6)δ7.88(s,1H),7.63-7.61(m,3H),7.36(d,J＝8.2Hz,2H),7.24(t,J＝8.5Hz,2H),6.87(d,J＝8.5Hz,2H),5.35(s,2H),4.00(s,1H),3.08(s,2H),2.77(t,J＝4.7Hz,4H),2.27(t,J＝4.6Hz,4H),2.07(s,3H).m/z(EI-MS):485.3[M]+.HPLC(80％methanol in water):tR＝3.595min,99.76％.
实施例65
Figure BDA0001978201020000332
3”-((5-氨基-6-氯嘧啶-4-基)氨基)-N，N，2'-三甲基-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-甲酰胺
步骤1:1-溴-4-氟-2-甲基-3-硝基苯的制备
按照实施例54步骤1的制备方法将2,6-二氟硝基苯替换为1-溴-2,4-二氟-3-硝基苯，收率86.7％；m.p.74℃-77℃；1H NMR(300MHz,CDCl3)δ7.72(d,J＝7.5,Hz,1H),7.03(d,J＝7.5Hz,1H),2.32(s,3H).m/z(EI-MS):233.9[M]+
步骤2：4'-氟-N，N，2'-三甲基-3'-硝基-[1,1'-联苯]-4-甲酰胺的制备
按照实施例54步骤2的制备方法，将(4-(甲氧基羰基)苯基)硼酸替换为(4-(二甲基氨基甲酰基)苯基)硼酸,收率76.9％；1H NMR(300MHz,CDCl3)δ7.89-7.86(m,2H),7.76(d,J＝7.5,Hz,1H),7.51-7.49(m,2H),7.26(d,J＝7.5Hz,1H),3.03(s,6H),2.30(s,3H).m/z(EI-MS):303.1[M]+.
步骤3：N，N，2′-三甲基-4′-(4-甲基哌嗪-1-基)-3′-硝基[1,1'-联苯]-4-甲酰胺的制备
按照实施例54步骤3的制备方法将4'-氟-3'-硝基-[1,1'-联苯基]-4-羧酸甲酯替换为4'-氟-N，N，2'-三甲基-3'-硝基-[1,1'-联苯]-4-甲酰胺。收率85.5％；m.p.110℃-112℃；1H NMR(300MHz,DMSO-d6)δ7.91(d,J＝5.7Hz,2H),7.60-7.57(m,3H),7.04(d,J＝5.6Hz,1H),3.39(t,J＝4.7Hz,4H),3.03(s,6H),2.54(t,J＝4.6Hz,4H),2.34(s,3H),2.17(s,3H).m/z(EI-MS):383.2[M]+.
步骤4：3′-氨基-N，N，2′-三甲基-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-甲酰胺的制备：
按照实施例54步骤4的制备方法将4'-(4-甲基哌嗪-1-基)-3'-硝基-[1,1'-联苯]-4-羧酸甲酯替换为N，N，2'-三甲基-4'-(4-甲基哌嗪-1-基)-3'-硝基[1,1'-联苯]-4-甲酰胺.收率80.5％；m.p.158℃-160℃；1H NMR(300MHz,DMSO-d6)δ7.91-7.89(m,2H),7.61-7.59(m,2H),6.68-6.64(m,2H),4.35(s,2H),3.39(t,J＝4.7Hz,4H),3.03(s,6H),2.54(s,4H),2.14(s,3H),2.09(s,3H).m/z(EI-MS):353.2[M]+.
步骤5：目标产物3”-((5-氨基-6-氯嘧啶-4-基)氨基)-N，N，2'-三甲基-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-甲酰胺的制备
按照实施例54步骤5的制备方法，得到化合物65.收率44.5％；m.p.165℃-167℃；1H NMR(300MHz,DMSO-d6)δ8.09(s,1H),7.87-7.85(m,2H),7.80(s,1H),7.58(d,J＝7.4Hz,2H),7.10(d,J＝7.5Hz,1H),6.86(d,J＝7.5Hz,1H),.5.49(s,2H),3.01-2.98(m,6H),2.87(s,4H),2.38(s,4H),2.18(s,3H),2.09(s,3H).m/z(EI-MS):480.2[M]+.HPLC(80％methanol in water):tR＝3.543min,96.37％.
实施例66
Figure BDA0001978201020000341
5'-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸甲酯步骤1：2'，4'-二氟-5'-硝基-[1,1'-联苯]-4-羧酸甲酯的制备
按照实施例23步骤1的制备方法将4-溴1-F硝基苯替换为1-溴-2,4-二氟-5-硝基苯,收率67.8％；m.p.134℃-136℃；1H NMR(300MHz,CDCl3)δ8.30(t,J＝5.7Hz,1H),7.97(d,J＝8.9Hz,2H),7.57(d,J＝5.8Hz,2H),7.24(t,J＝8.9Hz,1H),3.95(s,3H).m/z(EI-MS):294.1[M]+.
步骤2：2'-氟-4'-(4-甲基哌嗪-1-基)-5'-硝基-[1,1'-联苯]-4-羧酸甲酯的制备
按照实施例23步骤2的制备方法将4'-氟-3'-硝基-[1,1'-联苯基]-4-羧酸甲酯替换为2'，4′-二氟-5′-硝基-[1,1′-联苯]-4-羧酸甲酯。收率84.3％；m.p.137℃-140℃；1HNMR(300MHz,DMSO-d6)δ8.02-7.99(m,3H),7.68-7.65(m,2H),6.79(d,J＝7.5Hz,1H),3.95(s,3H),3.39(t,J＝4.7Hz,4H),2.54(t,J＝4.6Hz,4H),2.14(s,3H).m/z(EI-MS):374.1[M]+.
步骤3：5′-氨基-2′-氟-4′-(4-甲基哌嗪-1-基)-[1,1′-联苯]-4-羧酸甲酯的制备
按照实施例23步骤3的制备方法将4′-(4-甲基哌嗪-1-基)-3′-硝基-[1,1'-联苯]-4-羧酸甲酯替换为2'-氟-4'-(4-甲基哌嗪-1-基)-5'-硝基-[1,1'-联苯]-4-羧酸甲酯.收率80.6％；m.p.162℃-165℃；1H NMR(300MHz,DMSO-d6)δ8.00(d,J＝8.9Hz,2H),7.68(d,J＝8.8Hz,2H),6.56(d,J＝5.7Hz,1H),6.39(d,J＝8.9Hz,1H),4.35(s,2H),4.35(s,2H),3.95(s,3H),3.39(t,J＝4.7Hz,4H),2.54(t,J＝4.7Hz,4H),2.17(s,3H).m/z(EI-MS):344.2[M]+.
步骤4：目标产物5'-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸甲酯的制备：
按照实施例23步骤4类似的制备方法，得到化合物66，收率57.4％；m.p.220℃-223℃；1H NMR(300MHz,DMSO-d6)δ8.14(s,1H),8.02-7.99(m,2H),7.80(s,1H),7.66-7.64(m,2H),6.80(d,J＝5.7Hz,1H),6.56(d,J＝8.9Hz,1H),5.35(s,2H),3.95(s,3H),3.34(t,J＝4.7Hz,4H),2.57(t,J＝4.7Hz,4H),2.19(s,3H).HRMS(ESI):calcd.form/z C23H24ClFN6O2,[M+H]+471.1706,found 471.1706.HPLC(80％methanol in water):tR＝4.248min,98.83％.
实施例67
Figure BDA0001978201020000351
(5”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)(吗啉代)甲酮
步骤1：5”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸的制备
按照实施例23步骤5制备方法将3'-((5-氨基-6-氯嘧啶-4-基)氨基)-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸甲酯替换为5'-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸甲酯。收率82.7％；m.p.>250℃；1H NMR(300MHz,DMSO-d6)δ8.14-8.10(m,3H),7.80(s,1H),7.73-7.70(m,2H),6.80(d,J＝5.7Hz,1H),6.57(d,J＝8.9Hz,1H),5.34(s,2H),3.93(s,3H),3.34(t,J＝4.7Hz,4H),2.57(s,4H),2.12(s,3H).m/z(EI-MS):457.2[M]+.
步骤2：目标产物(5”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-基)(吗啉代)甲酮的制备
按照实施例23步骤6类似的制备方法，得到目标化合物67.收率78.4％；m.p.136℃-138℃；1H NMR(300MHz,DMSO-d6)δ8.09(s,1H),7.93(d,J＝8.7Hz,1H),7.82(s,1H),7.59(s,2H),7.51(d,J＝7.8Hz,2H),7.12(d,J＝8.6Hz,1H),5.40(s,2H),3.61(s,4H),2.97(s,4H),2.72(s,4H),2.54–2.51(m,4H),2.41(s,3H).HRMS(ESI):calcd.form/z C26H29ClFN7O2,[M+H]+526.2128,found 526.2130.HPLC(80％methanol in water):tR＝4.046min,96.85％.
实施例68
Figure BDA0001978201020000361
5”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-4”-(4-甲基哌嗪-1-基)-N-(2-吗啉代乙基)-[1,11,1′-联苯基]-4-甲酰胺
按照实施例67类似的制备方法，将吗啉替换为1-乙基吗啉，得到目标化合物68。收率78.4％；m.p.199℃-202℃；1H NMR(300MHz,DMSO-d6)δ8.47(s,1H),8.09(s,1H),7.95-7.92(m,3H),7.81(s,1H),7.62(d,J＝7.9Hz,2H),7.11(d,J＝12.4Hz,1H),5.39(s,2H),3.58(t,J＝4.6Hz,4H),3.41-3.40(m,4H),2.92(s,4H),2.56(s,4H),2.45(s,4H),2.29(s,3H).HRMS(ESI):calcd.form/z C28H34ClFN8O2,[M+H]+569.2550,found 569.2548.HPLC(80％methanol in water):tR＝4.049min,98.64％.
实施例69
Figure BDA0001978201020000362
5”-((5-氨基-6-氯嘧啶-4-基)氨基)-2′-氟-4”-(4-甲基哌嗪-1-基)-N-(3-吗啉代丙基)-[1,11,1′-联苯基]-4-甲酰胺
按照实施例67类似的制备方法，将吗啉替换为1-丙基吗啉，得到目标化合物69。收率78.4％；m.p.204℃-206℃；1H NMR(300MHz,DMSO-d6)δ8.55(s,1H),8.09(s,1H),7.93-7.90(m,3H),7.81(s,1H),7.63-7.60(m,2H),7.11(d,J＝12.3Hz,1H),5.39(s,2H),3.59(s,4H),3.32(s,4H),2.92(s,4H),2.58(s,4H),2.41(s,4H),2.31(s,3H),1.72(s,2H).HRMS(ESI):calcd.form/z C29H36ClFN8O2,[M+H]+583.2693,found 583.2699.HPLC(80％methanol in water):tR＝3.885min,99.38％.
实施例70
Figure BDA0001978201020000371
5”-((5-氨基-6-氯嘧啶-4-基)氨基)-2′-氟-N-(4-羟基环己基)-4”-(4-甲基哌嗪-1-基)-[1,11,1′-联苯基]-4-甲酰胺
按照实施例67类似的制备方法，将吗啉替换为哌啶-4-醇，得到目标化合物70.收率65.2％；m.p.200℃-203℃；1H NMR(300MHz,DMSO-d6)δ9.67(s,1H),8.06(s,1H),7.92(d,J＝8.4Hz,1H),7.82(s,1H),7.58(d,J＝7.7Hz,2H),7.47(d,J＝7.9Hz,2H),7.21(d,J＝12.2Hz,1H),5.44(s,2H),4.82(s,1H),4.01(s,2H),3.52(s,2H),3.16(s,8H),2.78(s,3H),1.76(s,2H),1.36(s,2H).HRMS(ESI):calcd.form/z C27H31ClFN7O2,[M+H]+554.2441,found554.2442.HPLC(80％methanol in water):tR＝4.057min,98.48％.
实施例71：
Figure BDA0001978201020000372
5”-((5-氨基-6-氯嘧啶-4-基)氨基)-2′-氟-4”-(4-甲基哌嗪-1-基)-N-((四氢-2H-吡喃-4-基)甲基)-[1,1'-联苯基]-4-甲酰胺
按照实施例67类似的制备方法，将吗啉替换为(四氢-2H-吡喃-4-基)甲胺，得到目标化合物71.收率75.2％；m.p.189℃-191℃；1H NMR(300MHz,DMSO-d6)δ8.54(s,1H),8.10(s,1H),7.94-7,91(m,3H),7.61(d,J＝8.0Hz,2H),7.11(d,J＝12.2Hz,1H),5.40(s,2H),3.87-3.83(m,2H),3.17(s,4H),2.92(s,4H),2.57(s,4H),2.30(s,3H),1.81(s,1H),1.23(s,4H).HRMS(ESI):calcd.form/z C28H33ClFN7O2,[M+H]+540.2285,found 540.2284.HPLC(100％methanol):tR＝7.989min,99.16％.
实施例72
Figure BDA0001978201020000373
5”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-氟-N，N-二甲基-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-甲酰胺
按照实施例67类似的制备方法，将吗啉替换为二甲基胺，得到目标化合物72.收率75.2％；m.p.157℃-159℃；1H NMR(300MHz,DMSO-d6)δ8.01(s,1H),7.83(dd,J＝8.7,3.7Hz,1H),7.72(d,J＝3.6Hz,1H),7.49(d,J＝7.1Hz,2H),7.45–7.36(m,2H),7.14–7.01(m,1H),5.35(s,2H),3.27-2.87(m,14H),2.40(s,3H).HRMS(ESI):calcd.form/z C24H27ClFN7O,[M+H]+484.2022,found 484.2022.HPLC(80％methanol in water):tR＝4.751min,95.34％.
实施例73
Figure BDA0001978201020000381
5'-((5-氨基-6-氯嘧啶-4-基)氨基)-2′-甲基-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸甲酯步骤1：4'-氟-2'-甲基-5'-硝基-[1,1'-联苯基]-4-羧酸甲酯的制备
按照实施例23步骤1的制备方法将4-溴1-F硝基苯替换为1-溴-4-氟-2-甲基-5-硝基苯。收率68.9％；m.p.133℃-134℃；1H NMR(300MHz,DMSO-d6)δ8.06(dd,J＝9.4,3.2Hz,2H),7.97(d,J＝7.7Hz,1H),7.62-7.57(m,3H),3.89(s,3H),2.33(s,3H).m/z(EI-MS):290.1[M]+.
步骤2：2'-甲基-4′-(4-甲基哌嗪-1-基)-5'-硝基-[1,1′-联苯]-4-羧酸甲酯的制备
按照实施例23步骤2的制备方法将4′-氟-3′-硝基-[1,1'-联苯基]-4-羧酸甲酯替换为4'-氟-2′-甲基-5'-硝基-[1,1′-联苯基]-4-羧酸甲酯。收率84.3％；m.p.153℃-155℃；1H NMR(300MHz,DMSO-d6)δ8.02-7.99(m,2H),7.84(s,1H),7.61-7.58(m,2H),7.09(s,1H),3.95(s,3H),3.39(t,J＝4.7Hz,4H),2.54(t,J＝4.6Hz,4H),2.32(d,J＝1.0Hz,3H),2.14(s,3H).m/z(EI-MS):370.1[M]+.
步骤3：5'-氨基-2'-甲基-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸甲酯的制备
按照实施例23步骤3的制备方法将4'-(4-甲基哌嗪-1-基)-3'-硝基-[1,1'-联苯]-4-羧酸甲酯替换为2'-甲基-4'-(4-甲基哌嗪-1-基)-5'-硝基-[1,1'-联苯]-4-羧酸甲酯。收率78.5％；m.p.158℃-160℃；1H NMR(300MHz,DMSO-d6)δ8.00(d,J＝8.9Hz,2H),7.68(d,J＝8.8Hz,2H),6.56(d,J＝5.7Hz,1H),6.39(d,J＝8.9Hz,1H),4.35(s,2H),4.35(s,2H),3.95(s,3H),3.39(t,J＝4.7Hz,4H),2.54(t,J＝4.7Hz,4H),2.17(s,3H).m/z(EI-MS):340.2[M]+.
步骤4：目标化合物5'-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-甲基-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸甲酯的制备
按照实施例23步骤4的制备方法将3'-氨基-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸甲酯替换为5'-氨基-2'-甲基-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸甲酯，收率45.9％；m.p.225℃-228℃；1H NMR(300MHz,DMSO-d6)δ8.14(s,1H),8.00(d,J＝7.7Hz,2H),7.80(d,J＝4.4Hz,2H),7.50–7.47(m,2H),7.08(s,1H),5.30(s,2H),2.86(d,J＝5.5Hz,4H),2.47(s,4H),2.22(d,J＝8.0Hz,6H).HRMS(ESI):calcd.form/z C24H27ClN6O2,[M+H]+467.1957,found 467.1953.HPLC(80％methanol in water):tR＝3.844min,97.34％.
实施例74
Figure BDA0001978201020000391
5”-((5-氨基-6-氯嘧啶-4-基)氨基)-2′-甲基-4”-(4-甲基哌嗪-1-基)-N-(3-吗啉代丙基)-[1,11,1′-联苯基]-4-甲酰胺
步骤1：5”-((5-氨基-6-氯嘧啶-4-基)氨基)-2′-甲基-4”-(4-甲基哌嗪-1-基)-[1,1′-联苯]-4-羧酸的制备
按照实施例23步骤5的制备方法将3'-((5-氨基-6-氯嘧啶-4-基)氨基)-4'-(4-甲基哌嗪-1-基)-[1,1'-联苯基]-4-羧酸甲酯替换为5“-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-甲基-4”-(4-甲基哌嗪-1-基)-[1,1'-联苯]-4-羧酸甲酯。收率79.4％；m.p.>250℃；1HNMR(300MHz,DMSO-d6)δ8.13-8.10(m,3H),7.80(s,1H),7.66-7.62(m,2H),6.85(s,1H),6.77(s,1H),5.30(s,2H),2.98(d,J＝5.1Hz,4H),2.47(s,4H),2.24(d,J＝8.0Hz,6H).m/z(EI-MS):453.2[M]+.
步骤2：目标化合物5”-((5-氨基-6-氯嘧啶-4-基)氨基)-2'-甲基-4”-(4-甲基哌嗪-1-基)-N-(3-吗啉代丙基)-[1,11,1'-联苯基]-4-甲酰胺的制备
按照实施例67类似的制备方法，得到化合物74.收率78.4％；m.p.204℃-206℃；1HNMR(300MHz,DMSO-d6)δ8.65(s,1H),8.10(s,1H),7.93-7.90(m,3H),7.80(s,1H),7.66-7.62(m,2H),7.11(d,J＝12.3Hz,1H),5.39(s,2H),3.59(s,4H),3.32(s,4H),2.92(s,4H),2.58(s,4H),2.41(s,4H),2.31(s,6H),1.72(s,2H).HRMS(ESI):calcd.form/zC20H39ClN8O2,[M+H]+579.2944,found 579.2950.HPLC(80％methanol in water):tR＝3.830min,98.82％.
测试实施例1：部分药效学试验及结果：
本发明基于与WDR5结合的一段MLL1肽段构造荧光分子探针，作为研究苯胺类化合物干扰WDR5蛋白-蛋白相互作用的方法，测定苯胺类化合物在不同浓度条件下的抑制率，进而计算IC50值。具体实验步骤：在384孔板中分别加入20μL WDR5蛋白、20μL荧光探针、20μL不同浓度梯度的化合物，孵育0.5小时后，利用多功能酶标仪在激发波长485nm发射波长为535nm的条件下读取荧光，计算mP值，利用以下公式计算抑制率后，再利用GraphPad软件计算IC50值，结果见表1。
Figure BDA0001978201020000392
干扰WDR5的蛋白-蛋白相互作用将会影响MLL1的H3K4甲基转移酶活性，进而调节Hox和Meis-1基因表达下调，抑制白血病细胞的增殖。
联苯类化合物DDO-2084是已经报道的能够抑制WDR5蛋白-蛋白相互作用、小分子抑制剂(Eur.J.Med.Chem.2016,124,480-489.)，本发明中DDO-2084作为阳性对照化合物。
表1.本发明化合物WDR5蛋白-蛋白相互作用抑制活性及甲基转移酶活性
Figure BDA0001978201020000401
a化合物的结构见具体实施例；bDDO-2084的结构：
Figure BDA0001978201020000411
未进行测试。
由表1可见，本发明的化合物具有较强的WDR5蛋白-蛋白相互作用抑制活性。表1中为本发明部分化合物是否具有抑制H3K4的甲基化水平作用的实验结果。实验结果表明本发明中对WDR5蛋白-蛋白相互作用具有抑制作用的化合物均能下调H3K4的甲基化水平。
本发明的部分化合物也进行了白血病细胞的抗增殖活性实验。表2为本发明的部分化合物评价抑制急性白血病细胞增殖活性的结果，其中MV4-11为人急性单核白血病细胞，Molm-13为人急性髓性白血病细胞。表2表明本发明的化合物具有明显抑制各种白血病细胞增殖的作用。
表2.本发明部分化合物对白血病细胞的抗增殖活性
Figure BDA0001978201020000412
a化合物的结构见具体实施例；bND为未进行测试；
同时部分化合物也进行了蛋白免疫印迹试验(Western-blot)在细胞水平对MLL1的甲基转移酶功能的抑制作用结果见图1.通过图1可知，实施例72能够剂量依赖性的抑制MLL1的催化活性而降低H3K4me1/2/3的表达含量。
同时，本发明的部分化合物也进行了细胞水平的RT-PCR实验，部分化合物的细胞水平的对下游Hox和Meis-1基因表达水平抑制结果见图2，通过图2可知，实施例72能够剂量依赖性的下调Hox和Meis-1基因表达水平。
另外本发明的部分化合物也进行了动物水平的抗肿瘤活性实验，选取白血病细胞MV4-11裸鼠移植瘤模型，进行口服给药，部分化合物对MV4-11肿瘤的抑制结果见图3，通过图3可知，实施例72能够在动物水平剂量依赖性抑制肿瘤的生长。

Claims (7)

1.一种苯胺类WDR5蛋白-蛋白相互作用抑制剂，其特征在于包含如通式(I)所示的化合物及其药学上可接受的盐：
Figure FDA0003694714340000011
其中，X代表N；
Y代表C；
R1、R2和R3选自氢、甲基、卤素或氨基；
R4代表哌嗪基或4-取代哌嗪基，取代基为甲基；
R5代表硝基、氨基、-NHCOR9、呋喃基、嘧啶基、吡啶基、取代三氮唑、取代苯基，取代基为单或双取代的卤素、-NHCOR10、-CONR11R12或-COOR10；R9代表苯基，R10代表氢、C1-C6烷基、C1-C6氨基取代烷基、3～7元环烷基、含氮或含氧的3～7元杂环、苯基；R11、R12代表氢、C1-C6烷基、苯基、未取代的含氮或含氧3～7元杂环或R11、R12连接形成含氮或含氧的3～7元杂环；
R6代表氢、卤素或甲基。
2.根据权利要求1所述的苯胺类WDR5蛋白-蛋白相互作用抑制剂，其特征在于所述药学上可接受的盐是通式(I)的无机酸盐和有机酸盐；无机酸盐为盐酸盐、氢溴酸盐、硫酸盐；有机酸盐为乙酸盐、乳酸盐、琥珀酸盐、富马酸盐、马来酸盐、柠檬酸盐、苯甲酸盐、甲磺酸盐或对苯甲磺酸盐。
3.一种权利要求1中通式(I)的制备方法，其特征在于包括如下反应步骤：
Figure FDA0003694714340000012
或：
Figure FDA0003694714340000021
4.一种药物组合物，其特征在于包含权利要求1所述的苯胺类WDR5蛋白-蛋白相互作用抑制剂。
5.一种权利要求1所述的苯胺类WDR5蛋白-蛋白相互作用抑制剂在制备治疗与WDR5酶功能有关适应症药物中的应用。
6.根据权利要求5所述的应用，其特征在于所述有关适应症为血液性肿瘤。
7.根据权利要求6所述的应用，其特征在于所述血液性肿瘤为急性白血病。
CN201910139980.6A 2019-02-26 2019-02-26 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途 Active CN109734674B (zh)

Priority Applications (14)

Application Number Priority Date Filing Date Title
CN201910139980.6A CN109734674B (zh) 2019-02-26 2019-02-26 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途
MX2021010218A MX2021010218A (es) 2019-02-26 2019-03-22 Inhibidor de la interaccion proteina-proteina wdr5 basado en anilina, metodo para preparar el mismo y uso del mismo.
CA3131285A CA3131285A1 (en) 2019-02-26 2019-03-22 Aniline-based wdr5 protein-protein interaction inhibitor, method for preparing the same, and use thereof
US17/434,353 US20220152027A1 (en) 2019-02-26 2019-03-22 Aniline-based wdr5 protein-protein interaction inhibitor, and preparation method and use thereof
AU2019431157A AU2019431157A1 (en) 2019-02-26 2019-03-22 Aniline WDR5 protein-protein interaction inhibitor, preparation method therefor and use thereof
EP19917469.9A EP3932910A4 (en) 2019-02-26 2019-03-22 ANILINE-WDR5-PROTEIN-PROTEIN INTERACTION INHIBITOR, METHOD FOR ITS PRODUCTION AND ITS USE
JP2021549174A JP2022526219A (ja) 2019-02-26 2019-03-22 アニリンベースのｗｄｒ５タンパク質間相互作用阻害剤、同様物を調製するための方法、およびその使用
KR1020217030807A KR20210137064A (ko) 2019-02-26 2019-03-22 아닐린계 wdr5 단백질-단백질 상호작용 억제제, 이의 제조 방법 및 그의 용도
PCT/CN2019/079160 WO2020172932A1 (zh) 2019-02-26 2019-03-22 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途
BR112021016861A BR112021016861A2 (pt) 2019-02-26 2019-03-22 Inibidor de interação proteína-proteína wdr5 à base de anilina, método para preparar o mesmo e uso do mesmo
SG11202109305XA SG11202109305XA (en) 2019-02-26 2019-03-22 Aniline-based WDR5 Protein-Protein Interaction Inhibitor, Method for Preparing the Same, and Use thereof
CL2021002234A CL2021002234A1 (es) 2019-02-26 2021-08-24 Inhibidor de la interacción proteína-proteína wdr5 basado en anilina, método para preparar el mismo y uso del mismo
IL285852A IL285852A (en) 2019-02-26 2021-08-25 Aniline-based wdr5 protein-protein interaction inhibitor, method for its preparation and use
CONC2021/0012375A CO2021012375A2 (es) 2019-02-26 2021-09-22 Inhibidor de la interacción proteína-proteína wdr5 basado en anilina, método para preparar el mismo y uso del mismo

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201910139980.6A CN109734674B (zh) 2019-02-26 2019-02-26 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途

Publications (2)

Publication Number Publication Date
CN109734674A CN109734674A (zh) 2019-05-10
CN109734674B true CN109734674B (zh) 2022-08-26

Family

ID=66368322

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201910139980.6A Active CN109734674B (zh) 2019-02-26 2019-02-26 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途

Country Status (14)

Country Link
US (1) US20220152027A1 (zh)
EP (1) EP3932910A4 (zh)
JP (1) JP2022526219A (zh)
KR (1) KR20210137064A (zh)
CN (1) CN109734674B (zh)
AU (1) AU2019431157A1 (zh)
BR (1) BR112021016861A2 (zh)
CA (1) CA3131285A1 (zh)
CL (1) CL2021002234A1 (zh)
CO (1) CO2021012375A2 (zh)
IL (1) IL285852A (zh)
MX (1) MX2021010218A (zh)
SG (1) SG11202109305XA (zh)
WO (1) WO2020172932A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023097422A1 (zh) * 2021-11-30 2023-06-08 首都医科大学附属北京口腔医院 Kdm6b的多肽序列及对间充质干细胞功能的调控应用
US20230293539A1 (en) * 2022-03-14 2023-09-21 Huyabio International, Llc Mll1-wdr5 protein-protein interaction inhibitor compounds and uses thereof
WO2024015478A2 (en) * 2022-07-14 2024-01-18 Huyabio International, Llc Combination therapies of wdr5 inhibitors and pd-1 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149827A1 (en) * 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
CN104844573A (zh) * 2015-04-17 2015-08-19 中国药科大学 嘧啶类btk抑制剂、其制备方法及医药用途
CN108715585A (zh) * 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10980807B2 (en) * 2016-02-09 2021-04-20 Inventisbio Llc Inhibitor of indoleamine-2,3-dioxygenase (IDO)
CN107382840B (zh) * 2016-05-16 2020-09-01 四川大学 吡啶类化合物及其作为idh功能变异突变体抑制剂类药物的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149827A1 (en) * 2010-05-24 2011-12-01 Glaxosmithkline Llc Compounds and methods
CN104844573A (zh) * 2015-04-17 2015-08-19 中国药科大学 嘧啶类btk抑制剂、其制备方法及医药用途
CN108715585A (zh) * 2018-04-23 2018-10-30 中国药科大学 苯基联三氮唑类mll1-wdr5蛋白-蛋白相互作用抑制剂

Also Published As

Publication number Publication date
IL285852A (en) 2021-10-31
KR20210137064A (ko) 2021-11-17
CN109734674A (zh) 2019-05-10
BR112021016861A2 (pt) 2021-11-30
WO2020172932A1 (zh) 2020-09-03
AU2019431157A1 (en) 2021-10-14
CL2021002234A1 (es) 2022-05-27
JP2022526219A (ja) 2022-05-24
EP3932910A1 (en) 2022-01-05
CA3131285A1 (en) 2020-09-03
MX2021010218A (es) 2021-10-26
SG11202109305XA (en) 2021-09-29
US20220152027A1 (en) 2022-05-19
CO2021012375A2 (es) 2021-11-19
EP3932910A4 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
DK2909192T3 (en) METHYLENE-CONNECTED QUINOLINYL MODULATORS OF ROR-GAMMA-T
JP4782344B2 (ja) ベンザゾール誘導体と、そのｊｎｋモジュレータとしての利用法
CN109734674B (zh) 苯胺类wdr5蛋白-蛋白相互作用抑制剂及其制法和用途
US20090004185A1 (en) Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents
JP2010522186A (ja) 化合物
CN110746424A (zh) Mk2抑制剂和其用途
JP2010522188A (ja) 化合物
CN112724145A (zh) 用于抑制shp2活性的吡嗪衍生物
JP2003321472A (ja) Ｇｒｋ阻害剤
CN109310671A (zh) 布鲁顿酪氨酸激酶抑制剂
AU2013331493A1 (en) Heteroaryl linked quinolinyl modulators of RORyt
CN111377907A (zh) 一种多取代苯氨基嘧啶衍生物及其制备方法和用途
KR20180094880A (ko) 5원 헤테로시클릭 아미드계 wnt 경로 억제제
KR20160127568A (ko) TNIK, IKKε 및 TBK1 억제제로서의 화합물 및 이를 포함하는 약학적 조성물
JP2023512038A (ja) 化合物及びその使用
CN107739368B (zh) N-取代-5-（（4-取代嘧啶-2-基）氨基）吲哚类衍生物及其制备方法和用途
CN111018860B (zh) 吡咯并三嗪类化合物及其应用
CN109666022B (zh) 三氮唑衍生物及其制备方法和用途
WO2013138396A1 (en) Dihydropyridopyrimidine and dihydronaphthyridine derivatives as tyrosine kinase inhibitors of especially vegf and pdgf
EP4324833A1 (en) Alkynylphenylbenzamide compound and use thereof
CN117396473A (zh) 血浆激肽释放酶的咪唑并吡啶基抑制剂
CN103396351A (zh) 吡咯烷类Bcl-2蛋白小分子抑制剂化合物及其制备、药物组合物与制药用途
JP6777904B2 (ja) 新規抗がん薬
CN114728963B (zh) 新型三唑吡啶衍生物和包括其的药物组合物
WO2024114574A1 (zh) 一种高选择性的plk4抑制剂及制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant